(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 3 January 2002 (03.01.2002)

PCT

(10) International Publication Number WO 02/00856 A2

M.; Ketelbuiserstraat 99, B-8810 Lichtervelde (BE). GEYSENS, Steven, C., J.; Steenbeekstraaje 8, B-9770

(51) International Patent Classification7: C12N 9/00 (21) International Application Number: PCT/IB01/01514 (22) International Filing Date: 29 June 2001 (29.06.2001)

Kruishoutem (BE).

NL, PT, SE, TR).

(74) Agent: PUST, Detlev, A.; Hoffmann . Eitle, Arabellastrasse 4, 81925 München (DE).

(81) Designated States (national): AU, CA, JP, KR, MX, NO.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/215,676

30 June 2000 (30.06.2000) US

(71) Applicant: FLANDERS INTERUNIVERSITY INSTI-TUTE FOR BIOTECHNOLOGY (VIB) [BE/BE]; Ri-

jvisschestraat 120, B-9052 Zwijnaarde (BE).

Published:

without international search report and to be republished upon receipt of that report

(72) Inventors: CONTRERAS, Roland; Molenstraat 53, B-9820 Merelbeke (BE). CALLEWAERT, Nico, L.,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: PROTEIN GLYCOSYLATION MODIFICATION IN PICIIIA PASTORIS

(57) Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an α -1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoprotiens with reduced glycosylation using such genetically engineered stains of Pichia are also provided.

Protein Glycosylation Modification in Pichia Pastoris

Field of the Invention

5

15

20

25

The present invention relates to methods and vectors useful for genetically modifying the glycosylation process in methylotrophic yeast strains for the purpose of producing glycoproteins with reduced glycosylation. The present invention further relates to methylotrophic yeast strains generated using the present methods and vectors, as well as glycoproteins produced from such genetically modified strains.

10 Background of the Invention

The methylotrophic yeasts including *Pichia pastoris* have been widely used for production of recombinant proteins of commercial or medical importance. However, production and medical applications of some therapeutic glycoproteins can be hampered by the differences in the protein-linked carbohydrate biosynthesis between these yeasts and the target organism such as a mammalian subject.

Protein N-glycosylation originates in the endoplasmic reticulum (ER), where an N-linked oligosaccharide (Glc₃Man₉GlcNAc₂) assembled on dolichol (a lipid carrier intermediate) is transferred to the appropriate Asn of a nascent protein. This is an event common to all eukaryotic N-linked glycoproteins. The three glucose residues and one specific α-1,2-linked mannose residue are removed by specific glucosidases and an α-1,2-mannosidase in the ER, resulting in the core oligosaccharide structure, Man₈GlcNAc₂. The protein with this core sugar structure is transported to the Golgi apparatus where the sugar moiety undergoes various modifications. There are significant differences in the modifications of the sugar chain in the Golgi apparatus between yeast and higher eukaryotes.

In mammalian cells, the modification of the sugar chain proceeds via 3 different pathways depending on the protein moiety to which it is added. That is, (1) the core sugar chain does not change; (2) the core sugar chain is changed by adding the N-acetylglucosamine-1-phosphate moiety (GlcNAc-1-P) in UDP-N-acetyl

glucosamine (UDP-GlcNAc) to the 6-position of mannose in the core sugar chain, followed by removing the GlcNAc moiety to form an acidic sugar chain in the glycoprotein; or (3) the core sugar chain is first converted into Man₅GlcNAc₂ by removing 3 mannose residues with mannosidase I; Man₅GlcNAc₂ is further modified by adding GlcNAc and removing 2 more mannose residues, followed by sequentially adding GlcNAc, galactose (Gal), and N-acetylneuraminic acid (also called sialic acid (NeuNAc)) to form various hybrid or complex sugar chains (R. Kornfeld and S. Kornfeld, *Ann. Rev. Biochem.* 54: 631-664, 1985; Chiba et al *J. Biol. Chem.* 273: 26298-26304, 1998).

5

10

15

20

25

In yeast, the modification of the sugar chain in the Golgi involves a series of additions of mannose residues by different mannosyltransferases ("outer chain" glycosylation). The structure of the outer chain glycosylation is specific to the organisms, typically with more than 50 mannose residues in *S. cerevisiae*, and most commonly with structures smaller than Man₁₄GlcNAc₂ in *Pichia pastoris*. This yeast-specific outer chain glycosylation of the high mannose type is also denoted hyperglycosylation.

Hyperglycosylation is often undesired since it leads to heterogeneity of a recombinant protein product in both carbohydrate composition and molecular weight, which may complicate the protein purification. The specific activity (units/weight) of hyperglycosylated enzymes may be lowered by the increased portion of carbohydrate. In addition, the outer chain glycosylation is strongly immunogenic which is undesirable in a therapeutic application. Moreover, the large outer chain sugar can mask the immunogenic determinants of a therapeutic protein. For example, the influenza neuraminidase (NA) expressed in *P. pastoris* is glycosylated with N-glycans containing up to 30-40 mannose residues. The hyperglycosylated NA has a reduced immunogenicity in mice, as the variable and immunodominant surface loops on top of the NA molecule are masked by the N-glycans (Martinet et al. *Eur J. Biochem.* 247: 332-338, 1997).

Therefore, it is desirable to genetically engineer methylotrophic yeast strains in which glycosylation of proteins can be manipulated and from which recombinant proteins can be produced that would not be compromised in structure or function by large N-glycan side chains.

5

Summary of the Invention

The present invention is directed to methods and vectors useful for genetically modifying the glycosylation process in methylotrophic yeast strains to produce glycoproteins with reduced glycosylation. Methylotrophic yeast strains generated using the present methods and vectors, as well as glycoproteins produced from such genetically modified strains are also provided.

In one embodiment, the present invention provides vectors useful for making genetically engineered methylotrophic yeast strains which are capable of producing glycoproteins with reduced glycosylation.

15

10

In one aspect, the present invention provides "knock-in" vectors which are capable of expressing in a methylotrophic yeast strain one or more proteins whose enzymatic activities lead to a reduction of glycosylation in glycoproteins produced by the methylotrophic yeast strain.

20

25

In a preferred embodiment, the knock-in vectors of the present invention include a nucleotide sequence coding for an α -1,2-mannosidase or a functional part thereof and are capable of expressing the α -1,2-mannosidase or the functional part in a methylotrophic yeast strain. A preferred nucleotide sequence is a nucleotide sequence encoding the α -1,2-mannosidase of a fungal species, and more preferably, Trichoderma reesei. Preferably, the α -1,2-mannosidase expression vector is engineered such that the α -1,2-mannosidase or a functional part thereof expressed from the vector includes an ER-retention signal. A preferred ER-retention signal is HDEL. The α -1,2-mannosidase coding sequence can be operable linked to a constitutive or inducible promoter, and a 3' termination sequence. The vectors can be

3

integrative vectors or replicative vectors. Particularly preferred α-1,2-mannosidase expression vectors include pGAPZMFManHDEL, pGAPZMFManMycHDEL, pFICZBMFManMycHDEL, pGAPZmManHDEL, pGAPZmMycManHDEL, pFIC9mMycManHDEL and pGAPZmMycManHDEL.

5

10

15

20

25

In another preferred embodiment, the knock-in vectors of the present invention include a sequence coding for a glucosidase II or a functional part thereof and are capable of expressing the glucosidase II or the functional part in a methylotrophic yeast strain. A preferred nucleotide sequence is a nucleotide sequence encoding the glucosidase II of a fungal species, and more preferably, *Saccharomyces cerevisiae*. Preferably, the glucosidase II expression vector is engineered such that the glucosidase II or a functional part thereof expressed from the vector includes an ER-retention signal. A preferred ER-retention signal is HDEL. The glucosidase II coding sequence can be operable linked to a constitutive or inducible promoter, and a 3' termination sequence. The vectors can be integrative vectors or replicative vectors. Particularly preferred glucosidase II expression vectors include pGAPZAGLSII, pPICZAGLSII, pAOX2ZAGLSII, pYPTIZAGLSII, pGAPADEglsII, pPICADEglsII, pAOX2ADEglsII, pYPTIADEglsII, pGAPZAglsIIHDEL and pGAPADEglsIIHDEL.

Expression vectors which include both of an α -1,2-mannosidase expression unit and a glucosidase II expression unit are also provided by the present invention.

In another aspect, the present invention provides "knock-out" vectors which, when introduced into a methylotrophic yeast strain, inactivate or disrupt a gene thereby facilitating the reduction in the glycosylation of glycoproteins produced in the methylotrophic yeast strain.

In one embodiment, the present invention provides a "knock-out" vector which, when introduced into a methylotrophic yeast strain, inactivates or disrupts the Ochl gene. A preferred Ochl knock-out vector is pBLURA5'PpOCH1.

Still another embodiment of the present invention provides vectors which include both a knock-in unit and a knock-out unit.

Furthermore, any of the knock-in or knock-out vectors of the present invention can also include a nucleotide sequence capable of expressing a heterologous protein of interest in a methylotrophic yeast.

Another embodiment of the present invention provides methods of modifying the glycosylation in a methylotrophic yeast by transforming the yeast with one or more vectors of the present invention.

5

10

15

20

25

Strains of a methylotrophic yeast which can be modified using the present methods include, but are not limited to, yeast strains capable of growth on methanol such as yeasts of the genera *Candida*, *Hansenula*, *Torulopsis*, and *Pichia*. Preferred methylotrophic yeasts are of the genus *Pichia*. Especially preferred are *Pichia* pastoris strains GS115 (NRRL Y-15851), GS190 (NRRL Y-18014), PPF1 (NRRL Y-18017), PPY120H, yGC4, and strains derived therefrom. Methylotrophic yeast strains which can be modified using the present methods also include those methylotrophic yeast strains which have been engineered to express one or more heterologous proteins of interest. The glycosylation on the heterologous proteins expressed from these previously genetically engineered strains can be reduced by transforming such strains with one or more of the vectors of the present invention

Methylotrophic yeast strains which are modified by practicing the present methods are provided in another embodiment of the present invention.

A further aspect of the present invention is directed to methods of producing glycoproteins with a reduced glycosylation.

In accordance with such methods, a nucleotide sequence capable of expressing a glycoprotein can be introduced into a methylotrophic yeast strain which has previously been transformed with one or more of the vectors of the present invention. Alternatively, a methylotrophic yeast strain which has been genetically engineered to express a glycoprotein can be transformed with one or more of the vectors of the present invention. Moreover, if a methylotrophic yeast strain is not transformed with a nucleotide sequence encoding a glycoprotein of interest or any of the vectors of the present invention, such yeast strain can be transformed, either

consecutively or simultaneously, with both a nucleotide sequence capable of expressing the glycoprotein and one or more vectors of the present invention.

Additionally, a methylotrophic yeast strain can be transformed with one or more of the present knock-in and/or knock-out vectors which also include a nucleotide sequence capable of expressing a glycoprotein in the methylotrophic yeast strain.

Glycoproteins products produced by using the methods of the present invention, i.e., glycoproteins with reduced N-glycosylation, are also part of the present invention.

Kits which include one or more of the vectors of the present invention, or one or more strains modified to produce glycoproteins with reduced glycosylation, are also provided.

Brief Description of the Drawings

5

15

20

25

Figure 1 depicts vectors carrying an HDEL-tagged Trichoderma reesei α-1,2-mannosidase expression cassette and describes the way in which these vectors were constructed according to methods known in the art. Abbreviations used throughout construction schemes: 5' AOX1 or AOX1 P: Pichia pastoris AOX1 promoter sequence; Amp R: ampicillin resistance gene; ColE1: ColE1 origin of replication; 3'AOX1: 3' sequences of the Pichia pastoris AOX1 gene; HIS4: HIS4 gene of Pichia pastoris. AOX TT: transcription terminator sequence of the Pichia pastoris AOX1 gene; ORF: open reading frame; S: secretion signal; P TEF1: the promoter sequence of the Saccharomyces cerevisiae transcription elongation factor 1 gene; P EM7: synthetic constitutive prokaryotic promotor EM7; Zeocin: Zeocin resistance gene; CYC1 TT: 3' end of the S. cerevisiae CYC1 gene; GAP: promoter sequence of the Pichia pastoris glyceraldehyde-3-phosphate dehydrogenase gene; PpURA3: Pichia pastoris URA3 gene. As can be seen in this figure, the Trichoderma reesei α-1,2-mannosidase was operably linked to the coding sequence for the S. cerevisiae \alpha-mating factor secretion signal sequence and further operably linked at the 3' terminus of the coding sequence to the coding sequence for an HDEL peptide. The

5

10

15

20

25

whole fusion construct was operably linked to either the *P. pastoris* AOX1 promoter (in pPIC9MFManHDEL) or to the *P. pastoris* GAP promotor (in pGAPZMFManHDEL).

Figure 2 depicts vectors carrying an HDEL-tagged *Mus musculus* α-1,2-mannosidase IB expression cassette and describes the way in which these vectors were constructed according to methods known in the art. As can be seen in this figure, the catalytic domain of the *Mus musculus* α-1,2-mannosidase IB was operably linked to the coding sequence for the *S. cerevisiae* α-mating factor secretion signal sequence and further operably linked at the 3' terminus of the coding sequence to the coding sequence for an HDEL peptide. The whole fusion construct was operably linked to either the *P. pastoris* AOX1 promoter (in pPIC9mManHDEL) or to the *P. pastoris* GAP promotor (in pGAPZmManHDEL). Furthermore, variants of the expression cassette were made in which the coding sequence for a cMyc epitope tag was inserted between the coding sequence for the *S. cerevisiae* α-Mating Factor secretion signal sequence and the coding sequence for the catalytic domain of the *Mus musculus* α-1,2-mannosidase IB. This expression cassette was also operably linked to either the *P. pastoris* AOX1 promoter (in pPIC9mMycManHDEL) or to the *P. pastoris* GAP promotor (in pGAPZmMycManHDEL).

Figure 3 depicts vectors carrying a MycHDEL tagged *Trichoderma reesei* α-1,2-mannosidase and the way in which these vectors were obtained. The resulting fusion construction was again operably linked to either the *P. pastoris* AOX1 promoter (in pPICZBMFManMycHDEL) or to the *P. pastoris* GAP promotor (in pGAPZMFManMycHDEL).

Figure 4 demonstrates the intracellular localization of the MycHDEL-tagged *Trichoderma reesei* α-1,2-mannosidase and indicates ER-targeting by immunofluorescence analysis. *Panel A* Western blotting. Yeast strains were grown in 10 ml YPG cultures to an OD₆₀₀=10, diluted fivefold and grown in YPM for 48 h. 1/50th of the culture medium and 1/65th of the cells were analysed by SDS-PAGE and

Western blotting with the mouse monoclonal 9E10 anti-Myc antibody. The position of molecular weight marker proteins are indicated with arrows. Lanes 1-5: cellular lysates. 1,2: pGAPZMFManMycHDEL transformants. 3: non-transformed PPY12OH (negative control). 4,5: pPICZBMFManMycHDEL transformants. Lanes 6-10: 5 culture media. 6: non transformed PPY12OH (negative control). 7,8: pGAPZMFManMycHDEL transformants. 9,10: pPICZBMFManMycHDEL transformants. Panel B Immunofluorescence microscopy. 1: phase contrast image of a P. pastoris cell (strain PPY12OH transformed with pGAPZMFManHDEL) at 1000x magnification. The nucleus is visible as an ellipse in the lower right quadrant of the 10 cell. 2: same cell as in 1, but in fluorescence microscopy mode to show localization of the T. reesei mannosidase-Myc-HDEL protein. The protein is mainly localized in a circular distribution around the nucleus (nuclear envelope), which is typical for an endoplasmic reticulum steady-state distribution. 3: phase contrast image of a P. pastoris cell (strain PPY12OH transformed with pGAPZMFManHDEL) at 1000x 15 magnification. 4: same cell in fluorescence microscopy to show localization of the Golgi marker protein OCH1-HA in P. pastoris strain PPY12OH. The dot-like distribution throughout the cytoplasm, with 3-4 dots per cell is typical for cis-Golgi distribution in P. pastoris.

Figure 5 depicts the co-sedimentation of mannosidase-MycHDEL with
20 Protein Disulfide Isomerase in sucrose density gradient centrifugation. The top panel
shows the distribution over the different fractions of the sucrose gradient of the
OCH1-HA Golgi marker protein. The middle panel shows this distribution for the
Protein Disulfide Isomerase endoplasmic reticulum marker protein. Finally, the
bottom panel shows the distribution of the MycHDEL-tagged *Trichoderma reesei* α25 1,2-mannosidase over the same fractions. It is concluded that the mannosidaseMycHDEL almost exactly matches the distribution of the ER marker PDI and thus
mainly resides in the ER of the *Pichia pastoris* yeast cells.

Figure 6 depicts the N-glycan analysis of *Trypanosoma cruzi trans*-sialidase coexpressed with *Trichoderma reesei* mannosidase-HDEL. Panel A: malto-

oligosaccharide size reference ladder. Sizes of the glycans are expressed in Glucose Units (GU) by comparison of their electrophoretic mobility to the mobility of these malto-oligosaccharides. Panel B: N-glycans derived from recombinant *Trypanosoma cruzi trans*-sialidase expressed in *Pichia pastoris*. The peak at GU=9,2 corresponds to Man₈GlcNAc₂. Panel C: same analytes as panel 2, but after overnight treatment with 3U/ml purified recombinant *T. reesei* α-1,2-mannosidase. Panel D: N-glycans derived from recombinant *trans*-sialidase co-expressed in *Pichia pastoris* with *T. reesei* mannosidase-HDEL (under control of the GAP promotor). The peak at GU=7,6 corresponds to the Man₅GlcNAc₂ peak in the profile of RNase B (Panel F). Panel E: same analytes as panel D, but after overnight treatment with 3 mU/ml purified recombinant *T. reesei* α-1,2-mannosidase. Panel F: N-glycans derived from bovine RNase B. These glycans consist of Man₅GlcNAc₂ to Man₈GlcNAc₂. Different

isomers are resolved, accounting for the number of peaks for Man₇GlcNAc₂.

5

10

Figure 7 depicts the processing of influenza haemagglutinin N-glycans by 15 HDEL-tagged Trichoderma reesei α-1,2-mannosidase and the HDEL-tagged catalytic domain of murine α-1,2-mannosidase IB. The Man₅GlcNAc₂ reference oligosaccharide runs at scan 1850 in this analysis (not shown). Panel 1: maltooligosaccharide size reference ladder. Panel 2: N-glycans derived from recombinant influenza haemagglutinin expressed in Pichia pastoris. The peak at scan 2250 20 corresponds to Man₉GlcNAc₂. Panel 3: N-glycans derived from recombinant haemagglutinin co-expressed in Pichia pastoris with T. reesei mannosidase-HDEL (under control of the GAP promotor). The peak at scan 1950 corresponds to Man₆GlcNAc₂. Panel 4: Same analytes as for panel 3, but after overnight treatment with 30 mU purified recombinant T. reesei α-1,2-mannosidase. Panel 5: N-glycans derived from recombinant haemagglutinin co-expressed in Pichia pastoris with mouse 25 mannosidase IB-HDEL (under control of the GAP promotor). Panel 6: same analytes as for panel 5, but after overnight treatment with 30 mU purified recombinant T. reesei α -1,2-mannosidase.

5

10

15

20

25

Figure 8 graphically depicts vector pBLURA5'PpOCH1 and the way in which it was constructed.

Figure 9 depicts the scheme for disrupting the *Pichia pastoris* OCH1 gene by single homologous recombination using pBLURA5'PpOCH1.

Figure 10 depicts the cell wall glycoprotein N-glycan analysis of the Och1-inactivated clone and three clones derived from this Och1-inactivated clone by transformation with pGAPZMFManHDEL. Panel 1 shows the analysis of a mixture of malto-oligosaccharides, the degree of polymerisation of which is given by the numbers on the very top of the figure. This analysis serves as a size reference for the other panels. On the vertical axis of all panels, peak intensity in relative fluorescence units is given. Panel 2-6: analysis of the cell wall glycoprotein N-glycans of the following strains: Panel 2, non-engineered P. pastoris strain yGC4; Panel 3, yGC4 transformed with pBLURA5'PpOch1; 4-6, three clones of the strain of Panel 3, supplementarily transformed with pGAPZMFManHDEL. Panel 7: the N-glycans derived from bovine RNaseB, consisting of a mixture of Man₅₋₉GlcNAc₂. As can be seen from comparison between panel 2 and 3 and reference to panel 7, transformation with pBLURA5'PpOch1 leads to a strongly increased abundance of the Man₈GlcNAc₂ substrate N-glycan (named peak 1 in Panel 2) of OCH1p. Peak 2 represents the Man₉GlcNAc₂ product of OCH1p. Furthermore, upon supplementary transformation of pGAPZMFManHDEL, the major glycan on the cell wall glycoproteins of three independent clones is the Man₅GlcNAc₂ end product (peak 3 in panel 4) of T. reesei α-1,2-mannosidase digestion of the Man₈GlcNAc₂ substrate.

Figure 11 depicts the analysis of exactly the same glycan mixtures as in Figure 10, but after an *in vitro* digest with 3mU/ml purified *Trichoderma reesei* α-1,2-mannosidase, overnight in 20 mM sodium acetate pH=5.0. Axis assignment is the same as in Figure 10. More Man₅GlcNAc₂ is formed in the pBLURA5'PpOch1 transformed strain (Panel 3) than in the parent strain (Panel 2). Peaks in all panels before scan 3900 come from contaminants and should be ignored in the analysis.

5

10

15

20

25

Figure 12 depicts the expression vector pGAPZAGLSII (SEQ ID NO: 18). P TEF1: promotor of S. cerevisiae transcription elongation factor gene. P Em7: synthetic prokaryotic promotor. Zeocin: zeocine resistance marker gene. CYC1 TT: transcription terminator of S. cerevisiae cytochrome C1 gene. Co1 E1: bacterial origin of replication. GAP: promotor of the P. pasttoris GAP gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene

Figure 13 depicts the expression vector pAOX2ZAGLSII (SEQ ID NO: 16). P TEF1: promotor of S. cerevisiae transcription elongation factor gene. P Em7: synthetic prokaryotic promotor. Zeocin: zeocine resistance marker gene. CYC1 TT: transcription terminator of S. cerevisiae cytochrome C1 gene. Co1 E1: bacterial origin of replication. AOX2 P: promotor of the P. pastoris AOX2 gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene

Figure 14 depicts the expression vector pPICZAGLSII (SEQ ID NO: 20).

P TEF1: promotor of S. cerevisiae transcription elongation factor gene. P Em7: synthetic prokaryotic promotor. Zeocin: zeocine resistance marker gene. CYC1 TT: transcription terminator of S. cerevisiae cytochrome C1 gene. Co1 E1: origin of replication. AOX1 P: promotor of the P. pastoris AOX1 gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene

Figure 15 depicts the expression vector pYPT1ZAGLSII ((SEQ ID NO: 22). P TEF1: promotor of S. cerevisiae transcription elongation factor gene. P Em7: synthetic prokaryotic promotor. Zeocin: zeocine resistance marker gene. CYC1 TT: transcription terminator of S. cerevisiae cytochrome C1 gene. Co1 E1: origin of replication. P YPT1: promotor of the P. pastoris YPT1 gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene.

Figure 16 depicts the expression vector pGAPADE1glsII (SEQ ID NO: 19). Amp R: Ampillicin resistance marker gene. ADE1: P. pastoris ADE1 selection

marker gene. GAP: promotor of the P. Pastoris GAP gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene

Figure 17 depicts the expression vector pAOX2ADE1glsII (SEQ ID NO: 17). Amp R: Ampillicin resistance marker gene. ADE1: P. pastoris ADE1 selection marker gene. AOX2 P: promotor of the P. pastoris AOX2 gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene.

5

10

15

20

Figure 18 depicts the expression vector pPICADE1glsII (SEQ ID NO: 21). Amp R: Ampillicin resistance marker gene. ADE1: P. pastoris ADE1 selection marker gene. AOX1 P: promotor of the P. pastoris AOX1 gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene.

Figure 19 depicts the expression vector pYPT1ADE1glsII (SEQ ID NO: 23). Amp R: Ampillicin resistance marker gene. ADE1: P. pastoris ADE1 selection marker gene. P YPT1: promotor of the P. pastoris YPT1 gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene.

Figure 20 depicts the expression vector pGAPZAglsIIHDEL (SEQ ID NO: 24). Amp R: Ampillicin resistance marker gene. ADE1: P. pastoris ADE1 selection marker gene. GAP: promotor of the P. pastoris GAP gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene.

Figure 21 depicts the expression vector pGAPADE1glsIIHDEL (SEQ ID NO: 25). P TEF1: promotor of S. cerevisiae transcription elongation factor gene. P Em7: synthetic prokaryotic promotor. Zeocin: zeocine resistance marker gene. CYC1 TT: transcription terminator of S. cerevisiae cytochrome C1 gene. Col E1: bacterial origin of replication. GAP: promotor of the P. pastoris GAP gene. GLS2: S. cerevisiae glucosidase II gene. AOX1 TT: transcription terminator of the P. pastoris AOX1 gene.

Figure 22 depicts the test of the GLSII activity assay using a commercially available yeast alpha-glucosidase (Sigma: Cat. No. G-5003). The assay mixture contains phosphate-citrate buffer pH 6.8, mannose, 2-deoxy-D-glucose, the substrate 4-methylumbellyferyl-alpha-D-glucopyranoside and alpha-glucosidase from Sigma. 1: assay mixture illuminated with UV-light after overnight incubation at 37 ° C; 2: same as 1, but this time, the assay mixture lacks the alpha-glucosidase; 3: same as 1, but this time, the assay mixture lacks the substrate.

Figure 23 depicts the results of the activity of recombinantly expressed GLSII from *Pichia pastoris*. All assay mixtures were incubated overnight at 37 °C and afterwards illuminated with UV-light. 1: assay with yeast alpha-glucosidase (Sigma: Cat. No. G-5003); 2: assay with the purified medium of strain 18 (PPY12-OH transformed with pGAPZAGLSII); 3: assay with purified medium of the WT PPY12-OH strain; 4: assay with the purified medium of strain H3 (PPY12-OH transformed with pGAPZAglsIIHDEL).

15

20

25

10

5

Detailed Description of the Invention

It has been established that the majority of N-glycans on glycoproteins leaving the endoplasmic reticulum (ER) of *Pichia* have the core Man₈GlcNAc₂ oligosaccharide structure. After the proteins are transported from the ER to the Golgi apparatus, additional mannose residues are added to this core sugar moiety by different mannosyltransferases, resulting in glycoproteins with large mannose side chains. Such hyperglycosylation of recombinant glycoproteins is undesirable in many instances. Accordingly, the present invention provides methods and vectors for genetically modifying methylotrophic yeast strains to produce glycoproteins with reduced glycosylation. Methylotrophic yeast strains generated using the present methods and vectors, as well as glycoproteins produced from such genetically modified strains are also provided.

In one embodiment, the present invention provides vectors useful for genetically modifying methylotrophic yeast strains to produce glycoproteins with reduced glycosylation.

5

10

15

20

25

In one aspect, the present invention provides "knock-in" vectors which are capable of expressing in a methylotrophic yeast strain one or more proteins whose enzymatic activities lead to a reduction of glycosylation in glycoproteins produced by the methylotrophic yeast strain. According to the present invention, such proteins include, e.g., an α -1,2-mannosidase, a glucosidase II, or functional parts thereof.

In a preferred embodiment, the vectors of the present invention include a sequence coding for an α -1,2-mannosidase or a functional part thereof and are capable of expressing the α -1,2-mannosidase or the functional part in a methylotrophic yeast strain.

An α -1,2-mannosidase cleaves the α -1,2-linked mannose residues at the non-reducing ends of Man₈GlcNAc₂, and converts this core oligosaccharide on glycoproteins to Man₅GlcNAc₂. *In vitro*, Man₅GlcNAc₂ is a very poor substrate for any *Pichia* Golgi mannosyltransferase, i.e., mannose residues can not be added to this sugar structure. On the other hand, Man₅GlcNAc₂ is the acceptor substrate for the mammalian N-acetylglucosaminyl-transferase I and is an intermediate for the hybridand complex-type sugar chains characteristic of mammalian glycoproteins. Thus, by way of introducing an α -1,2-mannosidase into methylotrophic yeasts such as *Pichia*, glycoproteins with reduced mannose content can be produced.

According to the present invention, the nucleotide sequence encoding an α -1,2-mannosidase for use in the expression vector of the present invention can derive from any species. A number of α -1,2-mannosidase genes have been cloned and are available to those skilled in the art, including mammalian genes encoding, e.g., a murine α -1,2-mannosidase (Herscovics et al. *J. Biol. Chem.* 269: 9864-9871, 1994), a rabbit α -1,2-mannosidase (Lal et al. *J. Biol. Chem.* 269: 9872-9881, 1994) or a human α -1,2-mannosidase (Tremblay et al. *Glycobiology* 8: 585-595, 1998), as well as fungal

5

10

15

20

25

genes encoding, e.g., an Aspergillus α -1,2-mannosidase (msdS gene), a Trichoderma reesei α -1,2-mannosidase (Maras et al. J. Biotechnol. 77: 255-263, 2000), or a Saccharomyces cerevisiae α -1,2-mannosidase. Protein sequence analysis has revealed a high degree of conservation among the eukaryotic α -1,2-mannosidases identified so far.

Preferably, the nucleotide sequence for use in the present vectors encodes a fungal α -1,2-mannosidase, more preferably, a *Trichoderma reesei* α -1,2-mannosidase, and more particularly, the *Trichoderma reesei* α -1,2-mannosidase described by Maras et al. *J. Biotechnol.* 77: 255-63 (2000).

According to the present invention, the nucleotide sequence can also code for only a functional part of an α -1,2-mannosidase.

By "functional part" is meant a polypeptide fragment of an α -1,2-mannosidase which substantially retains the enzymatic activity of the full-length protein. By "substantially" is meant at least about 40%, or preferably, at least 50% or more of the enzymatic activity of the full-length α -1,2-mannosidase is retained. For example, as illustrated by the present invention, the catalytic domain of the murine α -1,2-mannosidase IB constitutes a "functional part" of the murine α -1,2-mannosidase IB. Those skilled in the art can readily identify and make functional parts of an α -1,2-mannosidase using a combination of techniques known in the art. Predictions of the portions of an α -1,2-mannosidase essential to or sufficient to confer the enzymatic activity can be made based on analysis of the protein sequence. The activity of a portion of an α -1,2-mannosidase of interest, expressed and purified from an appropriate expression system, can be verified using *in vitro* or *in vivo* assays described hereinbelow.

In accordance with the present invention, an α -1,2-mannosidase or a functional part thereof expressed in a methylotrophic yeast strain preferably is targeted to a site in the secretory pathway where Man₈GlcNAc₂ (the substrate of α -1,2-

mannosidase) is already formed on a glycoprotein, but has not reached a Golgi glycosyltransferase which elongates the sugar chain with additional mannose residues.

Accordingly, in a preferred embodiment of the present invention, the α -1,2-mannosidase expression vector is engineered as such that the α -1,2-mannosidase or a functional part thereof expressed from the vector includes an ER-retention signal.

5

20

25

"An ER retention signal" refers to a peptide sequence which directs a protein having such peptide sequence to be transported to and retained in the ER. Such ER retention sequences are often found in proteins that reside and function in the ER.

Multiple choices of ER retention signals are available to those skilled in the art, e.g., the first 21 amino acid residues of the *S. cerevisiae* ER protein MNS1 (Martinet et al. *Biotechnology Letters* 20: 1171-1177, 1998). A preferred ER retention signal for use in the present invention is peptide HDEL (SEQ ID NO: 1). The HDEL peptide sequence, found in the C-terminus of a number of yeast proteins, acts as a retention/retrieval signal for the ER (Pelham *EMBO J.* 7: 913-918, 1988). Proteins with an HDEL sequence are bound by a membrane-bound receptor (Erd2p) and then enter a retrograde transport pathway for return to the ER from the Golgi apparatus.

According to the present invention, an ER retention signal can be placed anywhere in the protein sequence of an α -1,2-mannosidase, but preferably at the C-terminus of the α -1,2-mannosidase.

The α -1,2-mannosidase for use in the present invention can be further modified, e.g., by insertion of an epitope tag to which antibodies are available, such as Myc, HA, FLAG and His6 tags well-known in the art. An epitope-tagged α -1,2-mannosidase can be conveniently purified, or monitored for both expression and intracellular localization.

An ER retention signal and an epitope tag can be readily introduced into a protein of interest by inserting nucleotide sequences coding for such signal or tag into

the nucleotide sequence encoding the protein of interest, using any of the molecular biology techniques known in the art.

In another preferred embodiment, the vectors of the present invention include a sequence coding for a glucosidase II or a functional part thereof and are capable of expressing the glucosidase II or the functional part in the methylotrophic yeast strain.

5

10

15

20

25

It has been established that the initial N-linked oligosaccharide (Glc₃Man₉GlcNAc₂), transferred in the ER onto a protein, is cleaved in the ER by specific glucosidases to remove the glucose residues, and by a mannosidase to remove one specific α -1,2-linked mannose. It has been observed by the present inventors that some recombinant proteins expressed in *Pichia* have residual glucose residues on the sugar moiety when such proteins leave the ER for the Golgi apparatus. The residual glucose molecules present on the sugar structure prevent the complete digestion of the sugar moiety by an α -1,2-mannosidase, and the introduction of an exogenous glucosidase can facilitate the removal of these glucose residues.

According to the present invention, the nucleotide sequence encoding a glucosidase II can derive from any species. Glucosidase II genes have been cloned from a number of mammalian species including rat, mouse, pig and human. The glucosidase II protein from these mammalian species consists of an alpha and a beta subunit. The alpha subunit is about 110 kDa and contains the catalytic activity of the enzyme, while the beta subunit has a C-terminal HDEL ER-retention sequence and is believed to be important for the ER localization of the enzyme. The glucosidase II gene from *S. cerevisiae* has also been cloned (ORF YBR229c, located on chromosome II). This gene encodes a protein of about 110 kDa, which shows a high degree of homology to the mammalian alpha subunits.

A preferred glucosidase II gene for use in the present vectors is from a fungal species such as *Pichia pastoris* and *S. cerevisiae*. An example of a fungal glucosidase II gene is the *S. cerevisiae* glucosidase II alpha subunit gene.

According to the present invention, the nucleotide sequence can also encode only a functional part of a glucosidase II. By "functional part" is meant a polypeptide fragment of a glucosidase II which substantially retains the enzymatic activity of the full-length protein. By "substantially" is meant at least about 40%, or preferably, at least 50% or more of the enzymatic activity of the full-length glucosidase II is retained. Functional parts of a glucosidase II can be identified and made by those skilled in the art using a variety of techniques known in the art.

5

10

15

20

25

In a preferred embodiment of the present invention, the glucosidase II protein is engineered to include an ER retention signal such that the protein expressed in a methylotrophic yeast strain is targeted to the ER and retains therein for function. ER retention signals are as described hereinabove, e.g., the HDEL peptide sequence.

The glucosidase II for use in the present invention can be further modified, e.g., by insertion of an epitope tag to which antibodies are available, such as Myc, HA, FLAG, and His6 tag, which are well-known in the art.

According to the present invention, the "knock-in" vectors can include either or both of an α -1,2-mannosidase coding sequence and a glucosidase II coding sequence.

Further according to the present invention, the nucleotide sequence coding for the enzyme to be expressed (e.g., an α -1,2-mannosidase or a functional part thereof, or a glucosidase II or a functional part thereof) can be placed in an operable linkage to a promoter and a 3' termination sequence.

Promoters appropriate for expression of a protein in a methylotrophic yeast can include both constitutive promoters and inducible promoters. Constitutive promoters include e.g., the *Pichia pastoris* glyceraldehyde-3-phosphate dehydrogenase promoter ("the GAP promoter"). Examples of inducible promoters include, e.g., the *Pichia pastoris* alcohol oxidase I promoter ("the AOXI promoter") (U.S. Patent No. 4,855,231), or the *Pichia pastoris* formaldehyde dehydrogenase promoter ("the FLD promoter") (Shen et al. Gene 216: 93-102, 1998).

5

10

15

20

25

3' termination sequences are sequences 3' to the stop codon of a structural gene which function to stabilize the mRNA transcription product of the gene to which the sequence is operably linked, such as sequences which elicit polyadenylation. 3' termination sequences can be obtained from *Pichia* or other methylotrophic yeast. Examples of *Pichia pastoris* 3' termination sequences useful for the practice of the

Examples of *Pichia pastoris* 3' termination sequences useful for the practice of the present invention include termination sequences from the *AOX1* gene, *p40* gene, *HIS4* gene and *FLD1* gene.

The vectors of the present invention preferably contain a selectable marker gene. The selectable marker may be any gene which confers a selectable phenotype upon a methylotrophic yeast strain and allows transformed cells to be identified and selected from untransformed cells. The selectable marker system may include an auxotrophic mutant methylotrophic yeast strain and a wild type gene which complements the host's defect. Examples of such systems include the *Saccharomyces cerevisiae* or *Pichia pastoris HIS4* gene which may be used to complement *his4 Pichia* strains, or the *S. cerevisiae* or *Pichia pastoris ARG4* gene which may be used to complement *Pichia pastoris arg* mutants. Other selectable marker genes which function in *Pichia pastoris* include the *Zeo*^R gene, the *G418*^R gene, and the like.

The vectors of the present invention can also include an autonomous replication sequence (ARS). For example, U.S. Patent No. 4,837,148 describes autonomous replication sequences which provide a suitable means for maintaining plasmids in *Pichia pastoris*. The disclosure of U.S. Patent No. 4,837,148 is incorporated herein by reference.

The vectors can also contain selectable marker genes which function in bacteria, as well as sequences responsible for replication and extrachromosomal maintenance in bacteria. Examples of bacterial selectable marker genes include ampicillin resistance (Amp'), tetracycline resistance (Tet'), neomycin resistance, hygromycin resistance, and zeocin resistance (Zeo^R) genes.

5

10

15

20

25

According to the present invention, the nucleotide sequence encoding the protein to be expressed in a methylotrophic yeast can be placed in an integrative vector or a replicative vector (such as a replicating circular plasmid).

Integrative vectors are disclosed, e.g., in U.S. Patent No. 4,882,279 which is incorporated herein by reference. Integrative vectors generally include a serially arranged sequence of at least a first insertable DNA fragment, a selectable marker gene, and a second insertable DNA fragment. The first and second insertable DNA fragments are each about 200 nucleotides in length and have nucleotide sequences which are homologous to portions of the genomic DNA of the species to be transformed. A nucleotide sequence containing a structural gene of interest for expression is inserted in this vector between the first and second insertable DNA fragments whether before or after the marker gene. Integrative vectors can be linearized prior to yeast transformation to facilitate the integration of the nucleotide sequence of interest into the host cell genome.

Replicative and integrative vectors carrying either or both of an α -1,2-mannosidase coding sequence or a glucosidase II coding sequence can be constructed by standard techniques known to one of ordinary skill in the art and found, for example, in Sambrook et al. (1989) in Molecular Cloning: A *Laboratory Manual*, or any of a myriad of laboratory manuals on recombinant DNA technology that are widely available.

Preferred vectors of the present invention carrying an α-1,2-mannosidase expression sequence include pGAPZMFManHDEL, pGAPZMFManMycHDEL, pPICZBMFManMycHDEL, pGAPZmManHDEL, pGAPZmMycManHDEL, pPIC9mMycManHDEL and pGAPZmMycManHDEL, which are further described in the Examples hereinbelow.

Preferred vectors of the present invention carrying a glucosidase II expression sequence include pGAPZAGLSII, pPICZAGLSII, pAOX2ZAGLSII, pYPTIZAGLSII, pGAPADE1glsII, pPICADE1glsII, pAOX2ADE1glsII,

pYPTIADE1glsII, pGAPZAglsIIHDEL and pGAPADE1glsIIHDEL, which are further described in the Examples hereinbelow.

5

10

15

20

25

In another aspect, the present invention provides "knock-out" vectors which, when introduced into a methylotrophic yeast strain, inactivate or disrupt a gene thereby facilitating the reduction in the glycosylation of glycoproteins produced in the methylotrophic yeast strain.

In one embodiment, the present invention provides a "knock-out" vector which, when introduced into a methylotrophic yeast strain, inactivates or disrupts the Ochl gene.

The S. cerevisiae OCH1 gene has been cloned (Nakayama et al. EMBO J. 11: 2511-2519, 1992). It encodes a membrane bound α-1,6-mannosyltransferase, localized in the early Golgi complex, that is functional in the initiation of α-1,6-polymannose outer chain addition to the N-linked core oligosaccharide (Man₅GlcNAc₂ and Man₈GlcNAc₂) (Nakanishi-Shindo et al. J. Biol. Chem. 268: 26338-26345, 1993).

A *Pichia* sequence has been described in Japanese Patent Application No. 07145005 that encodes a protein highly homologous to the *S. cerevisiae* OCH1. For purpose of the present invention, this sequence is denoted herein as "the *Pichia* OCH1 gene". Those skilled in the art can isolate the OCH1 genes from other methylotrophic yeasts using techniques well known in the art.

According to the present invention, a disruption in the OCH1 gene of a methylotrophic yeast can result in either the production of an inactive protein product or no product. The disruption may take the form of an insertion of a heterologous DNA sequence into the coding sequence and/or the deletion of some or all of the coding sequence. Gene disruptions can be generated by homologous recombination essentially as described by Rothstein (in *Methods in Enzymology*, Wu et al., eds., vol 101:202-211, 1983).

To disrupt the Och1 gene by homologous recombination, an Och1 knockout vector can be constructed in such a way to include a selectable marker gene. The selectable marker gene is operably linked, at both 5' and 3' end, to portions of the

Och1 gene of sufficient length to mediate homologous recombination. The selectable marker can be one of any number of genes which either complement host cell auxotrophy or provide antibiotic resistance, including *URA3*, *LEU2* and *HIS3* genes. Other suitable selectable markers include the *CAT* gene, which confers chloramphenicol resistance on yeast cells, or the *lacZ* gene, which results in blue colonies due to the expression of active β-galactosidase. Linearized DNA fragments of an Och1 knock-out vector are then introduced into host methylotrophic yeast cells using methods well known in the art. Integration of the linear fragments into the genome and the disruption of the Och1 gene can be determined based on the selection marker and can be verified by, for example, Southern Blot analysis.

5

10

15

20

25

Alternatively, an Och1 knock-out vector can be constructed in such a way to include a portion of the Ochl gene to be disrupted, which portion is devoid of any Och1 promoter sequence and encodes none or an inactive fragment of the Och1 protein. By "an inactive fragment", it is meant a fragment of the Och1 protein which has, preferably, less than about 10% and most preferably, about 0% of the activity of the full-length OCH1 protein. Such portion of the OCH1 gene is inserted in a vector in such a way that no known promoter sequence is operably linked to the OCH1 sequence, but that a stop codon and a transcription termination sequence are operably linked to the portion of the Och1 gene. This vector can be subsequently linearized in the portion of the OCH1 sequence and transformed into a methylotrophic yeast strain using any of the methods known in the art. By way of single homologous recombination, this linearized vector is then integrated in the OCH1 gene. Two Och1 sequences are produced in the chromosome as a result of the single homologous recombination. The first Och1 sequence is the portion of the Och1 gene from the vector, which is now under control of the OCH1 promoter of the host methylotrophic yeast, yet cannot produce an active OCH1 protein as such Och1 sequence codes for no or an inactive fragment of the OCH1 protein, as described hereinabove. The second Och1 sequence is a full OCH1 coding sequence, but is not operably linked to any known promoter sequence and thus, no active messenger is expected to be formed for

synthesis of an active OCH1 protein. Preferably, an inactivating mutation is introduced in the OCH1 sequence, to the 5' end of the site of linearization of the vector and to the 3' end of the translation initiation codon of OCH1. By "inactivating mutation" it is meant a mutation introducing a stop codon, a frameshift mutation or any other mutation causing a disruption of the reading frame. Such mutation can be introduced into an Och1 sequence using any of the site directed mutagenesis methods known in the art. Such inactivating mutation ensures that no functional OCH1 protein can be formed even if there exist some promoter sequences 5' to the Och1 sequence in the knock-out vector.

A preferred Och1 knock-out vector of the present invention is pBLURA5'PpOCH1.

5

10

15

20

25

If desired, either or both of a mannosidase expression sequence and a glucosidase expression sequence can be carried on the same plasmid used to disrupt the OCH1 gene to create a "knock-in-and-knock-out" vector.

Additionally, any of the above-described vectors can further include a nucleotide sequence capable of expressing a glycoprotein of interest in a methylotrophic yeast strain.

Another aspect of the present invention is directed to methods of modifying methylotrophic yeast strains to reduce glycosylation on proteins produced by the methylotrophic yeast strains. In accordance with the present methods, methylotrophic yeast strains are modified by transforming into these yeast strains with one or more, i.e., at least one, knock-in and/or knock-out vectors of the present invention as described herein above.

Methylotrophic yeast strains which can be modified using the present methods include but are not limited to yeast capable of growth on methanol such as yeasts of the genera Candida, Hansenula, Torulopsis, and Pichia. A list of species which are exemplary of this class of yeasts can be found in C. Anthony (1982), The Biochemistry of Methylotrophs, 269. Pichia pastoris, Pichia methanolica, Pichia anomola, Hansenula polymorpha and Candida boidinii are examples of

5

10

15

20

25

methylotrophic yeasts useful in the practice of the present invention. Preferred methylotrophic yeasts are of the genus *Pichia*. Especially preferred are *Pichia pastoris* strains GS115 (NRRL Y-15851); GS190 (NRRL Y-18014) disclosed in U.S. Patent No. 4,818,700; PPF1 (NRRL Y-18017) disclosed in U.S. Patent No. 4,812,405; PPY120H and yGC4; as well as strains derived therefrom.

Methylotrophic yeast strains which can be modified using the present methods also include those methylotrophic yeast strains which have been genetically engineered to express one or more heterologous glycoproteins of interest. The glycosylation on the heterologous glycoproteins expressed from these previously engineered strains can be reduced by transforming such strains with one or more of the vectors of the present invention.

The vectors of the present invention can be introduced into the cells of a methylotrophic yeast strain using known methods such as the spheroplast technique, described by Cregg et al. 1985, or the whole-cell lithium chloride yeast transformation system, Ito et al. *Agric. Biol. Chem. 48*:341, modified for use in *Pichia* as described in EP 312,934. Other published methods useful for transformation of the plasmids or linear vectors include U.S. Patent No. 4,929,555; Hinnen et al. *Proc. Nat. Acad. Sci. USA* 75:1929 (1978); Ito et al. *J. Bacteriol.* 153:163 (1983); U.S. Patent No. 4,879,231; Sreekrishna et al. *Gene* 59:115 (1987). Electroporation and PEG1000 whole cell transformation procedures may also be used. Cregg and Russel *Methods in Molecular Biology: Pichia Protocols*, Chapter 3, Humana Press, Totowa, N.J., pp. 27-39 (1998).

Transformed yeast cells can be selected by using appropriate techniques including but not limited to culturing auxotrophic cells after transformation in the absence of the biochemical product required (due to the cell's auxotrophy), selection for and detection of a new phenotype, or culturing in the presence of an antibiotic which is toxic to the yeast in the absence of a resistance gene contained in the transformants. Transformants can also be selected and/or verified by integration of the

expression cassette into the genome, which can be assessed by e.g., Southern Blot or PCR analysis.

In one embodiment, a methylotrophic yeast strain is transformed with a vector which includes a nucleotide sequence coding for an α -1,2-mannosidase or a functional part thereof. The nucleotide sequence is capable of expressing the α -1,2-mannosidase or the functional part in the methylotrophic yeast strain, and is, preferably, integrated into the genome of the methylotrophic yeast strain.

5

10

15

20

25

The expression of an α -1,2-mannosidase introduced in a methylotrophic yeast strain can be verified both at the mRNA level, e.g., by Northern Blot analysis, and at the protein level, e.g., by Western Blot analysis. The intracellular localization of the protein can be analyzed by using a variety of techniques, including subcellular fractionation and immunofluorescence experiments. An ER localization of an α -1,2-mannosidase can be determined by co-sedimentation of this enzyme with a known ER resident protein (e.g., Protein Disulfide Isomerase) in a subcellular fractionation experiment. An ER localization can also be determined by an immunofluorescence staining pattern characteristic of ER resident proteins, typically a perinuclear staining pattern.

To confirm that an α -1,2-mannosidase or a functional part thereof expressed in a methylotrophic yeast strain has the expected mannose-trimming activity, both *in vitro* and *in vivo* assays can be employed. Typically, an *in vitro* assay involves digestion of an *in vitro* synthesized substrate, e.g., Man₈GlcNAc₂, with the enzyme expressed and purified from a methylotrophic yeast strain, and assessing the ability of such enzyme to trim Man₈GlcNAc₂ to, e.g., Man₅GlcNAc₂. In *in vivo* assays, the α -1,2-mannosidase or a part thereof is co-expressed in a methylotrophic yeast with a glycoprotein known to be glycosylated with N-glycans bearing terminal α -1,2-linked mannose residues in such yeast. The enzymatic activity of such an α -1,2-mannosidase or a part thereof can be measured based on the reduction of the number of α -1,2-linked mannose residues in the structures of the N-glycans of the

5

10

15

20

25

glycoprotein. In both *in vitro* and *in vivo* assays, the composition of a carbohydrate group can be determined using techniques that are well known in the art and are illustrated in the Examples hereinbelow.

In another embodiment, a methylotrophic yeast strain is transformed with a vector which includes a nucleotide sequence coding for a glucosidase II or a functional part thereof. The nucleotide sequence is capable of expressing the glucosidase II or the functional part in the methylotrophic yeast strain, and is, preferably, integrated into the genome of the methylotrophic yeast strain.

The enzymatic activity of a glucosidase II or a functional part thereof expressed in a transformed methylotrophic yeast strain can be assessed using a variety of assays. For example, methylotrophic yeast cells transformed with a sequence encoding a glucosidase II or a part thereof can be set to grow on solid medium containing a substrate of the glucosidase, e.g., 5-bromo-4-chloro-3-indolyl-α-Dglucopyranoside or 4-MU- α -D-Glc. When the enzyme is expressed by the *Pichia* and secreted extracellularly, the substrate is acted upon by the enzyme, giving rise to detectable signals around the colonies such as blue color or fluorescent glow. Alternatively, liquid culture medium containing the expressed protein molecules can be collected and incubated in test tubes with a substrate, e.g., p-nitrophenyl-α-Dglucopyranoside. The enzymatic activity can be determined by measuring the specific product released. Moreover, in vivo assays can be employed, where a glucosidase II is co-expressed in yeast with a glycoprotein known to be N-glycosylated with glucose residues, e.g., influenza neuraminidase. The enzymatic activity of the glucosidase II can be measured based on the reduction of the glucose content in the sugar chain(s) of the glycoprotein.

In still another embodiment of the present invention, a methylotrophic yeast strain is transformed with an Ochl knock-out vector. As a result of the transformation and integration of the vector, the genomic Ochl gene in the yeast strains is disrupted.

In a further embodiment of the present invention, a methylotrophic yeast strain is transformed with any combination of an α -1,2-mannosidase expression vector, a glucosidase II expression vector, and an Och1 knock-out vector. Such modification can be achieved by serial, consecutive transformations, i.e., introducing one vector at a time, or alternatively by co-transformation, i.e., introducing the vectors simultaneously.

5

10.

15

20

25

The modified methylotrophic yeast strains described herein above can be further modified if desired. For example, additional disruption of genes encoding any other *Pichia* mannosyltransferases can be made. Genes encoding mammalian enzymes can also be introduced to produce glycoproteins having hybrid- or complex-type N-glycans, if desired.

Methylotrophic yeast strains which are modified by using the present methods, i.e., by transforming with one or more of the vectors of the present invention, form another embodiment of the present invention.

It should be understood that certain aspects of the present invention, especially the introduction of an intracellularly expressed α -1,2-mannosidase activity, are also useful to obtain a reduced glycosylation of the O-linked glycans on glycoproteins produced in a methylotrophic yeast, as it is known in the art that these O-linked glycans consist mainly of α -1,2-linked mannose residues. O-linked glycans as used herein refers to carbohydrate structures linked to serine or threonine residues of glycoproteins.

A further aspect of the invention is directed to methods of producing a glycoprotein with reduced glycosylation in a methylotrophic yeast, especially a glycoprotein heterologous to the methylotrophic yeast.

"A glycoprotein" as used herein refers to a protein which, in methylotrophic yeasts, is either glycosylated on one or more asparagines residues or on one or more serine or threonine residues, or on both asparagines and serine or threonine residues.

The term "reduced glycosylation" refers to a reduced size of the carbohydrate moiety on the glycoprotein, particularly with fewer mannose residues, when the glycoprotein is expressed in a methylotrophic yeast strain which has been modified in accordance with the present invention, as compared to a wild type, unmodified strain of the methylotrophic yeast.

5

10

15

20

25

In accordance with the present invention, the production of a glycoprotein of interest with reduced glycosylation can be achieved in a number of ways. A nucleotide sequence capable of expressing a glycoprotein can be introduced into a methylotrophic yeast strain which has been previously modified in accordance with the present invention, i.e., a strain transformed with one or more of the vectors of the present invention and capable of producing glycoproteins with reduced glycosylation. Alternatively, a methylotrophic yeast strain which has already been genetically engineered to express a glycoprotein can be transformed with one or more of the vectors of the present invention. Otherwise, if a methylotrophic yeast strain does not express a glycoprotein of interest, nor is the strain transformed with any of the vectors of the present invention, such yeast strain can be transformed, either consecutively or simultaneously, with both a nucleotide sequence capable of expressing the glycoprotein and one or more vectors of the present invention. Additionally, a methylotrophic yeast strain can be transformed with one or more of the present knockin and/or knock-out vectors which also include a nucleotide sequence capable of expressing a glycoprotein in the methylotrophic yeast strain.

The nucleotide sequence capable of expressing a glycoprotein in a methylotrophic yeast can be made to include from 5' to 3', a promoter, a sequence encoding the glycoprotein, and a 3' termination sequence. Promoters and 3' termination sequences which are suitable for expression of a glycoprotein can include any of those promoters and 3' termination sequences described hereinabove.

The nucleotide sequence for expression of a glycoprotein can include additional sequences, e.g., signal sequences coding for transit peptides when secretion of a protein product is desired. Such sequences are widely known, readily available

and include Saccharomyces cerevisiae alpha mating factor prepro (amf), Pichia pastoris acid phosphatase (PHO1) signal sequence and the like.

5

10

15

20

25

The nucleotide sequence for expression of a glycoprotein can be placed on a replicative vector or an integrative vector. The choice and construction of such vectors are as described hereinabove.

The nucleotide sequence capable of expressing a glycoprotein can be carried on the same replicative plasmid as a plasmid-borne α -1,2-mannosidase or glucosidase II expression unit. Alternatively, the nucleotide sequence containing the glycoprotein coding sequence is carried on a separate plasmid or integrated into the host genome.

Glycoproteins produced can be purified by conventional methods. Purification protocols can be determined by the nature of the specific protein to be purified. Such determination is within the ordinary level of skill in the art. For example, the cell culture medium is separated from the cells and the protein secreted from the cells can be isolated from the medium by routine isolation techniques such as precipitation, immunoadsorption, fractionation or a variety of chromatographic methods.

Glycoproteins which can be produced by the methods of the present invention include, e.g., *Bacillus amyloliquefaciens* α -amylase, *S. cerevisiae* invertase, *Trypanosoma cruzi trans*-sialidase, HIV envelope protein, influenza virus A haemagglutinin, influenza neuraminidase, Bovine herpes virus type-1 glycoprotein D, human angiostatin, human B7-1, B7-2 and B-7 receptor CTLA-4, human tissue factor, growth factors (e.g., platelet-derived growth factor), tissue plasminogen activator, plasminogen activator inhibitor-I, urokinase, human lysosomal proteins such as α -galactosidase, plasminogen, thrombin, factor XIII and immunoglobulins. For additional useful glycoproteins which can be expressed in the genetically engineered *Pichia* strains of the present invention, see Bretthauer and Castellino, *Biotechnol*.

5

10

15

20

25

Appl. Biochem. 30: 193-200 (1999), and Kukuruzinska et al. Ann Rev. Biochem. 56: 915-44 (1987).

Glycoproteins produced by using the methods of the present invention, i.e., glycoproteins with reduced glycosylation, are also part of the present invention.

Still another aspect of the present invention provides kits which contain one or more of the knock-in vectors, knock-out vectors, or knock-in-and-knock-out vectors of the present invention described above. More particularly, a kit of the present invention contains a vector capable of expressing an α -mannosidase I in a methylotrophic yeast, a vector capable of expressing a glucosidase II in a methylotrophic yeast, a vector capable of disrupting the Och1 gene in a methylotrophic yeast, a vector capable of expressing both a glucosidase II and an α -mannosidase, a vector a vector capable of disrupting the Och1 gene and capable of expressing either or both of a glucosidase II and an α -mannosidase, or any combinations thereof.

The kit can also include a nucleotide sequence which encodes and is capable of expressing a heterologous glycoprotein of interest. Such nucleotide sequence can be provided in a separate vector or in the same vector which contains sequences for knocking-in or knocking out as described hereinabove.

In addition, the kit can include a plasmid vector in which a nucleotide sequence encoding a heterologous protein of interest can be subsequently inserted for transformation into and expression in a methylotrophic yeast. Alternatively, the knock-in or knock-out vectors in the kits have convenient cloning sites for insertion of a nucleotide sequence encoding a heterologous protein of interest.

The kit can also include a methylotrophic yeast strain which can be subsequently transformed with any of the knock-in, knock-out or knock-in-and-knock-out vectors described hereinabove. The kit can also include a methylotrophic yeast strain which has been transformed with one or more of the knock-in or knock-out vectors. Furthermore, the kit can include a methylotrophic yeast strain which has been

transformed with a nucleotide sequence encoding and capable of expressing a heterologous glycoprotein of interest.

The present invention is further illustrated by the following examples.

$\underline{\textbf{Example 1}}$ Introduction of α -1,2-Mannosidase to the ER-Golgi Border

1.1 Plasmids

Plasmid	Promoter	Enzyme	Tag
pGAPZMFManHDEL	GAP	T. reesei α-1,2-mannosidase	
pGAPZMFManMycHDEL	GAP	T. reesei α-1,2-mannosidase	Мус
pPICZBMFManMycHDEL	AOX1	T. reesei α-1,2-mannosidase	Мус
pGAPZMFmManHDEL	GAP	mouse mannosidase IB	
		catalytic domain	
pGAPZMFmMycManHDEL	GAP	mouse mannosidase IB	Мус
		catalytic domain	

5

10

15

20

The *Trichoderma reesei* α-1,2-mannosidase gene has been isolated and described by Maras et al. (*J. Biotechnol.* 77;255-263, 2000). The sequence of this gene is available at NCBI Genbank under Accession No. AF212153. A construction fragment was generated by PCR using the pPIC9MFmanase plasmid (same as pPP1MFmds1 described by Maras et al. (2000)) as the template and using the following oligonucleotide primers: 5'-GACTGGTTCCAATTGACAAGC-3' (SEQ ID NO:2) and 5'-AGTCTAGATTACAACTCGTCGTGAGCAAGGTGGCCGCCCCG TCG-3' (SEQ ID NO:3). The resulting product contained the 3' end of the *Pichia pastoris* AOXI promoter, the prepro-signal sequence of the *S. cerevisiae* α-mating factor, the open reading frame of the *Trichoderma reesei* α-1,2-mannosidase cloned in frame with the signal sequence, the coding sequence for HDEL, a stop codon and an *Xba* I restriction site. This fragment was digested with *Eco* RI and *Xba* I, removing the 5' sequences up to the mannosidase ORF, and then cloned into the vector pGAPZαA (Invitrogen, Baarn, The Netherlands) which had been digested with *Eco* RI and *Xba* I, thus restoring the fusion with the *S. cerevisiae* α-mating factor signal

sequence. The resulting plasmid was named pGAPZMFManHDEL and is graphically depicted in **Figure 1**. The ORF sequence of the MFManHDEL fusion in pGAPZMFManHDEL is set forth in SEQ ID NO: 14.

In order to introduce the coding sequence for a c-Myc tag between the catalytic domain and the HDEL-signal, the 3' end of the ORF of T. reesei α-1,2-5 mannosidase was PCR-amplified using a sense primer 5'-CCATTGAGGACGCATGCCGCGCC-3' (SEQ ID NO: 4) (containing an Sph I restriction site) and an antisense primer GTATCTAGATTACAACTCGTCGTGCAGATCCTCTTCTGAGATGAGTTTTTGT 10 TCAGCAAGGTGGCCGCCCGTCGTGATGATGAA (SEQ ID NO: 5) (containing the coding sequences of the c-Myc tag and the HDEL signal, followed by a stop codon and an Xba I restriction site). The resulting PCR product was digested with Sph I and Xba I, purified by agarose gel electrophoresis and inserted into pGAPZMFManHDEL which had been cut with the same restriction enzymes, resulting in plasmid 15 pGAPZMFManMycHDEL. To put the ORF of pGAPZMFManMycHDEL under the control of the inducible AOXI promoter, the entire ORF was liberated from pGAPZMFManMycHDEL with Bst BI and Xba I, and cloned in pPICZB (Invitrogen, Baarn, The Netherlands), resulting in pPICZBMFManMycHDEL.

Cloning of the mouse mannosidase IB catalytic domain with concomitant

20 addition of the coding sequence for a C-terminal HDEL-tag was done by PCR on a
mouse cDNA library (mRNA isolated from the L929 cell line induced with
cycloheximide and mouse Tumor Necrosis Factor. Average insert length of the cDNA
library was 2000 bp). The PCR oligonucleotide primers used were:
5'AACTCGAGATGGACTCTTCAAAACACAAACGC3' (SEQ ID NO: 6) and

25 5'TTGCGGCCGCTTACAACTCGTCGTGTCGGACAGCAGGATTACCTGA3'
(SEQ ID NO: 7). The product contained a 5' Xho I site and the coding sequence for Cterminal HDEL-site, followed by a stop codon and a Not I site at the 3' end. The
product was cloned in pGAPZαA via the Xho I /Not I sites in the PCR product and the
vector, resulting in an in frame fusion of the mouse mannosidase catalytic domain

with the S. cerevisiae α -mating factor signal sequence. The sequence of the entire open reading frame generated is set forth in SEQ ID NO: 15.

1.2 Yeast Transformation and Genomic Integration

5 <u>Table 2</u>

DNA transformed
pGAPZMFManHDEL
pPIC9MFManHDEL
pPIC9mManHDEL
pPIC9mMycManHDEL
pGAPZmManHDEL
pGAPZmMycManHDEL
pGAPZMFManHDEL
pGAPZmManHDEL
pGAPZmMycManHDEL
pGAPZMFManMycHDEL
pPICZBMFManMycHDEL
pPIC9InfluenzaNeuraminidase
pGAPZMFManHDEL
pPIC9Glucoseoxidase

All transformations to *Pichia pastoris* were performed with electroporation according to the directions of Invitrogen. Transformants of vectors carrying the Zeocin resistance gene were selected on YPD containing $100 \mu g/ml$ Zeocine

(Invitrogen, Baarn, the Netherlands) and 1M sorbitol. Selection of transformants of pPIC9 derivatives was done on minimal medium lacking histidine and containing 1M sorbitol. Genomic integration of the expression cassettes was verified using PCR on genomic DNA purified from the *Pichia* strains using the Yeast Miniprep method (Nucleon). In all cases concerning the Trichoderma reesei gene fusions, the primers used were the sense primer 5'-CCATTGAGGACGCATGCCGCGCC-3' (SEQ ID NO: 8), which annealed to the 3' half of the mannosidase ORF, and the antisense primer 3' AOXI 5'-GCAAATGGCATTCTGACATCCT-3' (SEO ID NO: 9), which annealed to the AOXI transcription terminator that was present in all our expression constructs. For the control of genomic integration of the mouse mannosidase transgenes, PCR was done using the sense primer 5'GAP 5'GTCCCTATTTCAATCAATTGAA3' (SEQ ID NO: 10, annealing to the GAP promoter or 5'AOXI 5'GACTGGTTCCAATTGACAAGC3' (SEQ ID NO:11), annealing to AOXI promoter), and the antisense primer 3'AOXI (above). For the expression constructs containing a Myc tagged Trichoderma reesei α-1,2-mannosidase expression unit, further evidence for genomic integration was obtained using Southern Blotting with the entire MFManMycHDEL ORF (³²P labelled using HighPrime, Boehringer Mannheim) as a probe.

20 1.3 Expression of α-1,2-mannosidase

5

10

15

25

Expression of an α -1,2-Mannosidase in GS115 strains expressing influenza virus haemagglutinin was verified by qualitative Northern blot. Expression of an α -1,2-Mannosidase in PPY120H strains was verified by anti-Myc Western blot.

Qualitative Northern Blot -- Total RNA was purified from Pichia strains and the yield was determined spectrophotometrically. Northern blotting was performed according to standard procedures and an estimate of the quantity of RNA loaded was made using methylene blue staining of the blot, visualizing the rRNA

bands. The blot was probed with a *Clal/NarI* fragment of the mannosidase, labelled with ³²P using HighPrime (Boehringer Mannheim).

SDS-PAGE and Western Blotting -- Total yeast cell lysates were prepared by washing the cells twice with PBS, followed by boiling in 1 volume of 2x concentrated Laemmli loading buffer for 5 min. The lysate was spun briefly in a microcentrifuge prior to gel loading and only the supernatant was loaded. For the analysis of proteins secreted into the growth media, the proteins were precipitated from 200 ul of these media using desoxycholate/trichloroacetic acid according to standard procedures. The pellet was redissolved in 2x concentrated Laemmli loading buffer and the solutions were pH-corrected using Tris. SDS-PAGE was performed and followed by semidry electroblotting to nitrocellulose membranes. For Western Blotting, the 9E10 anti-Myc and the anti-HA mouse monoclonals (Boehringer Mannheim) were used at a concentration of lµg/ml, and the rabbit anti-PDI antiserum (Stressgen) was used at a dilution of 1/500. The secondary antibodies were goat antimouse IgG conjugated to alkaline phosphatase for the monoclonals and goat antirabbit IgG conjugated to peroxidase for the polyclonal (secondary antibodies from Sigma). Detection was performed using the NBT/BCIP system for alkaline phosphatase and the Renaissance substrate (NENBiosciences) for peroxidase. Imaging of the latter blot result was done on a Lumilager imaging device (Boehringer Mannheim).

The results shown in **Figure 4** indicated that the great majority of the HDEL-tagged protein was retained intracellularly, both when expressed from the strong constitutive GAP promoter and when expressed from the strong inducible AOXI promoter.

25

20

5

10

15

1.4 Localization of α-1,2-Mannosidase

Isopycnic sucrose density gradient centrifugation -- To determine the localization of the HDEL-tagged mannosidase, subcellular fractionation was carried

out using cells expressing the mannosidase-Myc-HDEL from the strong constitutive GAP promoter.

Briefly, 0.5 g of wet weight yeast cells were lysed using 4 x 1 min vortexing with 4.5 g glass beads in 1 ml lysis-buffer (50 mM Tris-HCL pH 7.5 containing 0.6 M sorbitol, 10 mM β-mercaptoethanol and 5 mM MgCl₂). Between vortexing periods, the mixture was placed on ice for 5 min. The supernatant was collected and the glass beads were washed once with lysis-buffer, and the supernatant of this washing step was added to the first supernatant. This lysate was subjected to a differential centrifugation procedure. The P10000 pellet was solubilized in 0.5 ml of a 60% sucrose solution in lysis buffer. This solution was placed at the bottom of an Ultraclear ultracentrifuge tube (Beckman) of 14 x 89 mm. Subsequently, 1.5 ml each of sucrose solutions of 55, 50, 45, 42.5, 40, and 37.5% were carefully layered over each other. The tube was filled to the edge with 35% sucrose. Isopycnic sucrose gradient centrifugation was performed for 14 h at 180,000g in a Beckman SW 41 rotor in a Beckman Model L8-70 preparative ultracentrifuge. After completion, 1ml fractions were collected from the top and partially dialysed from excess sucrose. evaporated to dryness in a vacuum centrifuge. After redissolving the pellet in Laemmli buffer, the samples were subjected to SDS-PAGE in triplicate and the Western blots were treated with anti-HA, anti-Myc or anti-PDI ("PDI" for Protein Disulfide Isomerase), respectively.

10

15

20

25

The results illustrated almost exact cosedimentation of the MFManMycHDEL protein with the Protein Disulfide Isomerase marker protein (which is also targeted with a HDEL signal sequence) (Figure 5). In the same assay, the HA-tagged OCH1 was distributed over the whole gradient, with the highest abundance in fractions having a density lower than that of the fractions containing the mannosidase and the PDI. This result indicated that the mannosidase was targeted to the expected location (the ER-Golgi boundary) by the addition of an HDEL signal. In contrast, the mannosidase without HDEL, expressed from inducible alcohol oxidase I

promoter (which was of comparable strength as the GAP promoter), was secreted at a high level of about 20 mg/l.

Immunofluorescence microscopy -- To confirm the correct targeting of the mannosidase-Myc-HDEL, an immunofluorescence microscopy experiment was performed.

5

10

15

20

25

Briefly, yeast cultures were grown to OD600 in YPD (for pGAPZMFManMycHDEL) or in YMP following a YPGlycerol growth phase for pPICZBMFManMycHDEL. Formaldehyde was added to the yeast cultures to a final concentration of 4% and incubated for 10 min at room temperature. Cells were pelleted and resuspended in 50mM potassium phosphate buffer pH 6.5 containing 1mM MgCl₂ and 4% formaldehyde and incubated for 2h at room temperature. After pelleting, the cells were resuspended to an OD₆₀₀=10 in 100 mM potassium phosphate buffer pH 7.5 containing 1mM MgCl₂ and EDTA-free CompleteTM protease inhibitor cocktail (Boehringer Mannheim). To 100 μl of cell suspension, 0.6 μl of β-mercaptoethanol and 20µl of 20,000 U/ml Zymolyase 100T (ICN) were added, followed by a 25 minute incubation with gentle shaking. The cells were washed twice in the incubation buffer and added to poly-lysine coated cover slips (these are prepared using adhesive rings normally in use for reinforcing perforations in paper). Excess liquid was blotted with a cotton swab and the cells were allowed to dry at 20°C. All blocking, antibody incubation and washing steps are performed in PBS containing 0.05% bovine serum albumin. Primary antibodies are used at 2µg/µl and secondary antibodies conjugated to flurophores (Molecular probes) were used at 5µg/µl. The nucleus was stained with the nucleic acid stain HOECHST 33258. After fixation and cell wall permeabilization, the integrity of the yeast cell morphology was checked in phase contrast microscopy and after immunostaining, the slides were examined under a Zeiss Axiophot fluroresensce microscope equipped with a Kodak digital camera. Images were processed using Macprobe 4.0 software and prepared with Corel Photopaint 9.0.

The Golgi marker protein OCH1-HA gave the typical Golgi staining pattern described in the literature (speckle-like staining). Staining with the 9E10 monoclonal anti-Myc antibody, recognizing mannosidase-Myc-HDEL, gave a perinuclear staining pattern with some disparate staining in the cytoplasm, highly indicative for an ER targeting (Figure 4).

Based on the foregoing experiments, it is concluded that the *Trichoderma* reesei mannosidase-Myc-HDEL was targeted to the ER-Golgi boundary.

Example 2

Co-expression of Mannosidase-HDEL with Recombinant Glycoproteins

10

15

20

25

5

Co-expression of Mannosidase-HDEL with the Trypanosoma cruzi trans-Sialidase

The cloning of a *Trypanosoma cruzi trans*-sialidase gene coding for an active trans-sialidase member without the C-terminal repeat domain has been described by Laroy et al. (Protein Expression and Purification 20: 389, 2000) which is incorporated herein by reference. The sequence of this Trypanosoma cruzi transsialidase gene is available through NCBI Genbank under the Accession No. AJ276679. For expression in P. pastoris, the entire gene was cloned in pHILD2 (Invitrogen, San Diego, CA), creating pHILD2-TS. To allow better secretion, pPIC9-TS was created in which trans-sialidase was linked to the prepro secretion signal of the yeast α-mating factor. Plasmids pPIC9-TSE and pCAGGS-prepro-TSE were created where the epitope E-tag was added to the C-terminal of the trans-sialidase to allow easy detection and purification. The construction of pHILD2-TS, pPIC9-TSE and pCAGGS-prepro-TSE has been described by Laroy et al. (2000), incorporated herein by reference. The vectors used in the construction were made available through http://www.belspo.be/bccm/lmbp.htm#main for pCAGGS (No. LMBP 2453), Invitrogen, San Diego, CA for pHILD2 and pPIC9, and Pharmacia Biotech for pCANTAB-5E.

Plasmid pPIC9-TSE was linearized with SstI and was transformed into *P. pastoris* GS115 (*his4*) strain by electroporation according to the manufacturer's instructions (Invitrogen). One of the transformants was further transformed with plasmid pGAPZMFManHDEL, establishing a strain co-expressing Mannosidase-HDEL and the *Trypanosoma cruzi trans*-sialidase.

Fermentation and protein purification was according to the procedures described by Laroy et al. (2000).

5

10

15

20

25

Purified *trans*-sialidase was subject to carbohydrate analysis according to Callewaert et al., *Glycobiology* 11, 4, 275-281, 2001. Briefly, the glycoproteins were bound to the PVDF membrane in the wells of a 96-well plate, reduced, alkylated and submitted to peptide-N-glycosidase F deglycosylation. The glycans were derivatised with 8-amino-1,3,6-pyrenetrisulfonic acid by reductive amination. Subsequently, the excess free label was removed using Sephadex G10-packed spin columns and the glycans were analysed by electrophoresis on a 36 cm sequencing gel on an ABI 377A DNA-sequencer and detected using the built-in argon laser. Digests with 3 mU/ml purified *T. reesei* α-1,2-mannosidase (described by Maras et al., *J. Biotechnol.* 77, 255-63, 2000) were also performed in 20 mM sodium acetate pH=5.0. The glycans derived from 1 μg of the purified recombinant glycoproteins were used as the substrate. 1U of the α-1,2-mannosidase is defined as the amount of enzyme that releases 1 μmol of mannose from baker's yeast mannan per minute at 37°C and pH=5.0.

As can be seen in **Figure 6**, panel B, the major N-glycan on *trans*-sialidase was Man₈GlcNAc₂ (Compare with panel F, representing an analysis of the N-glycans of bovine RNAseB. The one but last peak in this profile is Man₈GlcNAc₂, the first peak is Man₅GlcNAc₂). *In vitro*, this glycan was digestible to Man₅GlcNAc₂ with α-1,2-mannosidase (**Figure 6**, panel C). In the N-glycan profile of the *trans*-sialidase co-expressed with mannosidase-HDEL, the major peak corresponded to Man₅GlcNAc₂ (**Figure 6**, panel D).

5

10

15

20

25

Co-expression of Mannosidase-HDEL with the Influenza A virus haemagglutinin

The Influenza A virus haemagglutinin was known to be glycosylated in *Pichia pastoris* with high-mannose N-glycans containing 9-12 mannose residues (Saelens et al. *Eur. J. Biochem.* 260: 166-175, 1999). The effect of a co-expressed mannosidase on the N-glycans of the haemagglutinin was assessed in an N-glycan profiling method described below. In addition, to compare the efficiency of the *Trichoderma* enzyme (having a temperature optimum of 60°C) with a mammalian mannosidase having a temperature optimum of 37°C, the catalytic domain of the mouse mannosidase IB from a mouse cDNA-library was cloned and tagged with a HDEL signal by PCR amplification. This ORF was cloned after the prepro-signal sequence of the *S. cerevisiae* α-mating factor under the control of the GAP promoter. Expression of the mannosidase-HDEL transgenes on the mRNA level was confirmed by qualitative Northern blotting.

The haemagglutinin was expressed and purified from a non-mannosidase expressing control strain and from a strains co-expressing the Trichoderma reesei mannosidase-HDEL or the mouse mannosidase IB-HDEL according to the procedure described by Kulakosky et al. Glycobiology 8: 741-745 (1998). The purified haemagglutin was subjected to PNGase F digestion as described by Saelens et al. Eur. J. Biochem. 260: 166-175, 1999. The proteins and glycans were precipitated with 3 volumes of ice-cold acetone and the glycans were extracted from the pellet with 60% methanol. Following vacuum evaporation, the glycans were labeled with 8-amino-1,3,6 pyrenetrisulfonic acid by adding 1 µl of a 1:1 mixture of 20 mM APTS in 1.2M citric acid and 1M N_aCNBH₃ in DMSO and incubating for 16h at 37°C at the bottom of a 250 µl PCR-tube. The reaction was stopped by the addition of 10 µl deionized water and the mixture was loaded on a 1.2 cm Sephadex G10 bed packed to dryness in a microspin-column by centrifugation in a swinging bucket rotor, which provided for a flat resin surface. After loading, 50 µl deionised water was carefully added to the resin bed and the spin column was briefly centrifuged for 5 seconds at 750g in a tabletop centrifuge. This elution process was repeated twice and all the eluates were

5

10

15

20

25

pooled and evaporated to dryness in a Speedvac vacuum centrifuge (Savant). The labeled glycans were reconstituted in 1.5 µl gel loading buffer containing 50% formamide and 0.5 µl Genescan 500TM, labeled with rhodamine (Perkin Elmer Bioscience), serving as an internal reference standard. This mixture was loaded on a DNA-sequencing gel containing 10% of a 19:1 mixture of acrylamide:bisacrylamide (Biorad, Hercules, CA, USA) and made up in the standard DNA-sequencing buffer (89 mM Tris, 89 mM borate, 2.2 mM EDTA). Polymerization of the gel was catalyzed by the addition of 200 µl 10% ammononiumpersulfate solution in water and 20 µl TEMED. The gel was of the standard 36 cm well-to-read length and was run on an Applied Biosystems Model 373A DNA-sequencing apparatus. Prerunning of the gel was done at 1000 V for 15 min. and after loading, the gel was electrophoresed for 8h at 1250 V without heating. This methodology gives a limit of detection of 10 fmol per peak. The data were analysed with Genescan 3.0 software.

As shown in **Figure** 7, the *Trichoderma reesei* α -1,2-mannosidase provided the most complete reduction in the number of α -1,2-mannoses present on the N-glycans. The N-glycan processing by mouse mannosidase IB-HDEL was less efficient than by the *Trichoderma reesei* α -1,2-mannosidase.

Despite the efficient removal of α-1,2-mannoses from the N-glycans of haemagglutinin, no Man₅GlcNAc₂ was obtained. Even after digestion of the N-glycans with 3 mU of purified *Trichoderma reesei* α-1,2-mannosidase, only Man₆GlcNAc₂ was obtained as the smallest sugar chain. These results indicated that the remaining residues were possibly α-1,6-linked mannoses, originating from the initiating OCH1 α-1,6-mannosyltransferase enzymatic activities. OCH1 was observed to be localized to very early part of the Golgi apparatus and could act on the N-glycans of haemagglutinin before complete digestion of the Man₈GlcNAc₂ precursor to Man₅GlcNAc₂ by the mannosidases-HDEL. Thus, for proteins whose glycans are efficiently modified by the α-1,6-mannosyltransferase, an inactivation of the OCH1

gene coding for the transferase would be desirable in order to obtain proteins with $Man_5GlcNAc_2$.

Example 3 Inactivation of the *Pichia* Och1 Gene:

A *Pichia pastoris* sequence was found in the GenBank under Accession

No. E12456 and was described in Japanese Patent Application No. 07145005,
incorporated herein by reference. This sequence shows all typical features of an α1,6-mannosyltransferase and is most homologous to the *S. cerevisiae* OCH1, thus
referred to herein as the *Pichia pastoris* Och1 gene.

10

15

20

25

First, the full ORF of the *Pichia pastoris* Och1 gene was PCR cloned in pUC18 to obtain plasmid pUC18pOch1. pUC18pOch1 was cut with HindIII, bluntended with T4 polymerase, then cut with XbaI, releasing a fragment containing the 5' part of the *Pichia pastoris* Och1 gene. This fragment was ligated into the vector pBLURA IX (available from the Keck Graduate Institute, Dr. James Cregg, http://www.kgi.edu/html/noncore/faculty/cregg/cregg.htm), which had been cut with *Eco* RI, blunt-ended with T4 polymerase, and then cut with *Nhe* I. This ligation generated pBLURA5'PpPCH1, as shown in **Figure 8**.

Disruption of this *Pichia* OCH1 gene in the *Pichia* genome was achieved by single homologous recombination using pBLURA5'PpOCH1, as illustrated in **Figure 9**. As a result of the single homologous recombination, the Och1 gene on the *Pichia* chromosome was replaced with two Och1 sequences: one consisted only about the first one third of the full Och1 ORF, the other had a full Och1 ORF without a Och1 promoter. Single homologous recombination was achieved as follows. Cells of the *Pichia* strain yGC4 were transformed by electroporation with pBLURA5'PpOCH1 which had been linearized with the single cutter *Bst* BI. About 500 transformants were obtained on minimal medium containing 1M sorbitol, biotin, arginine, adenine and histidine and incubation at 27°C. Thirty-two of these transformants were picked and re-selected under the same conditions. Twelve clones were further analyzed for correct genomic integration of the cassette by PCR. Seven of the twelve URA prototrophic clones contained the cassette in the correct locus.

One of the Och1-inactivated clones was also further transformed with pGAPZMFManHDEL to produce "supertransformants". Both the Ochl-inactivated clone and three supertransformants also expressing the ManHDEL were evaluated in cell wall glycan analysis as follows. Yeast cells were grown in 10 ml YPD to an OD₆₀₀=2 and mannoproteins were prepared by autoclaving the yeast cells in 20 mM sodium citrate buffer pH7 for 90 min at 120 °C and recovery of the supernatant after centrifugation. Proteins were precipitated from this supernatant with 3 volumes of cold methanol. The protein preparation obtained in this way was used for N-glycan analysis using DSA-FACE as described by Callewaert et al. (2001) Glycobiology 11, 275-281. As shown in Figure 10, there was an increased amount of MangGlcNAc2 glycan in the Ochl-inactivanted clone as compared to parent strain yGC4, indicative of a reduced activity of the Ochl enzyme. In all three supertransformants which also expressed the HDEL-tagged α-1,2 mannosidase, the production of Man₅GlcNAc₂ was observed. Furthermore, upon digestion of the same glycan mixtures with 3 mU/ml purified recombinant Trichoderma reesei α-1,2-mannosidase, more Man₅GlcNAc₂ was formed in the strain transformed with pBLURA5'PpOCH1 than in the parent strain (Figure 11, compare panel 2 and 3).

10

15

20

These results confirmed that the lack of a production of Man₅ glycans on recombinantly produced proteins such as haemagglutinin from cells expressing α -1,2-mannosidase were due to the activity of the Och1 protein. These results further indicate that the production of glycoproteins with Man₅ glycans could be facilitated by the inactivation of the Och1 gene.

Example 4

Expression of Glucosidase II in Pichia pastoris

4.1 Amplification of the GLSII alpha subunit ORF from S. cerevisiae.

Genomic DNA was prepared from the S. cerevisiae strain INVS (α, leu2-3, 112 his3Δ1, trpl-289, ura3-52), using the Nucleon kit (Amersham). A touch-down PCR reaction was performed using this genomic DNA as template and the LA TaKaRa polymerase (ImTec Diagnostics). The sequence of the PCR primers was based on the known sequence of the S. cerevisiae GLSII ORF:

Sense primer: 5' CCG <u>CTC GAG</u> ATG GTC CTT TTG AAA TGG CTC 3'

(SEQ ID NO:12)

Antisense primer: 5' CCG GGC CCA AAA ATA ACT TCC CAA TCT TCA

15 G 3' (SEQ ID NO:13)

4.2 Cloning of the S. cerevisiae glucosidase II ORF into Pichia pastoris expression vectors.

Construction of the glucosidase II expression vectors -- The PCR fragment
was digested with Xho I/Apa I and ligated into the pGAPZA vector (Invitrogen),
thereby placing the ORF under the transcriptional control of the GAP promoter.
Using this strategy, the myc and the His6 tag were placed in frame to the C-terminus
of Glucosidase II, creating pGAPZAGLSII. The complete ORF of pGAPZAGLSII
was then sequenced to ensure that no mutations were generated in the PCR reaction.

The sequence of the vector pGAPZAGLSII was set forth in SEQ ID NO: 18. The GLSII ORF from the pGAPZAGLSII vector was cloned into vector pPICZA (Invitrogen) to create pPICZAGLSII, thereby placing the ORF under the transcriptional control of the AOXI promoter. The GLSII ORF from the pGAPZAGLSII vector was cloned into vector pAOX2ZA, thereby placing the ORF under the transcriptional control of the AOX2 promoter. This vector was created by

replacing the multi cloning site of vector pAOX2ZB with the multi cloning site of pPICZA. Vector pAOX2ZB was generated by replacing the AOX1 promotor of pPICZB by the AOX2 promotor region of the AOX2 gene (Martinet et al., Biotechnology Letters 21). The AOX2 promotor region was generated by PCR on 5 Pichia genomic DNA with the sense primer 5'GACGAGATCTTTTTTCAGACCATATGACCGG 3' (SEQ ID NO: 26) and the antisense primer 5'GCGGAATTCTTTTCTCAGTTGATTTGTTTGT 3' (SEQ ID NO: 27). The GLSII ORF from the pGAPZGLSII vector was cloned into vector pYPT1ZA to create pYPTIZAGLSII, thereby placing the ORF under the 10 transcriptional control of the YPT1 promoter. Vector pYPTZA was created by replacing the AOX1 promoter of pPICZA by the YPT1 promoter present on the plasmid pIB3 (GenBank accession number AF027960)(Sears et al., Yeast 14, pg 783-790, 1998). All constructs contain the phleomycin resistance gene. The resulting final expression vectors (pGAPZAGLSII, pAOX2ZAGLSII, pPICZAGLSII and pYPT1ZAGLSII) are depicted in Figures 12-15. 15

Similar expression vectors were constructed, carrying the Ampicillin resistance marker and the *Pichia* ADE1 selection marker. In principle, the Zeocin resistance expression cassette of the plasmids pAOX2ZAGLSII, pGAPZAGLSII and pYPT1ZAGLSII was replaced by the Ampicillin and *Pichia* ADE1 cassette of the vector pBLADE IX (Cregg, J.M.) to result in the vectors pAOX2ADE1glsII, pGAPADE1glsII and pYPT1ADE1glsII. Vector pPICADE1glsII was obtained by inserting the glucosidase II open reading frame into the multiple cloning site of the vector pBLADE IX (Cregg, J.M.). The resulting final expression vectors (pGAPADE1glsII, pAOX2ADE1glsII, pPICADE1glsII and pYPT1ADE1glsII) are depicted in **Figures 16-20**.

20

25

Adding the ER retention tag HDEL to Glucosidase II expression vectors —
The following primers were used to generate an HDEL-containing PCR fragment:
Primer 1: 5'GCG GGT CGA C/CA C/GA C/GA A/CT G/TG A/GT TTT AGC CTT
Sal I H D E L stop

AGA CAT GAC 3'

Primer 2: 5'CAG GAG CAAA GCT <u>CGT ACG</u> AG 3'

Spl I

(SEQ ID NO:28)

(SEQ ID NO:29)

PCR was performed on pGAPZAGLSII with Taq pol., at 60°C. The PCR fragment of 225 bp was cut with Sal I/Spl I and ligated into the Sal I/Spl I opened pGAPZAGLSII vector, creating plasmid pGAPZAglsIIHDEL. The sequence of plasmid pGAPZAglsIIHDEL is set forth in SEQ ID NO: 24. The construction strategy and the resulting final expression vectors (pGAPZAglsIIHDEL and pGAPADE1glsIIHDEL) are depicted in Figures 20-21.

4.3 Transformation of a Pichia pastoris strain.

Transformation was performed using the conventional electroporation techniques, as described by Invitrogen. Cells of the *Pichia pastoris* strain PPY12-OH were transformed with pGAPZGLSII which had been cut with the single cutter *Avr* II. Transformants were selected based on their resistance to zeocin.

Genomic analysis of the transformants -- Genomic DNA was prepared from some zeocin resistant *Pichia* transformants. A PCR reaction was performed on the genomic DNA in order to determine whether or not the glucosidase II gene was integrated into the yeast genome. PCR was performed using Taq DNA polymerase (Boehinger) (2.5 mM MgCl₂, 55°C for annealing). The primers were the same as the ones we used for the amplification of the ORF on *S. cerevisiae* genomic DNA. pGAPZAGLSII transformants were confirmed by the presence of a specific PCR product indicative of the glucosidase II ORF.

25

30

15

20

4.4 Expression and secretion of the S. cerevisiae glucosidase II alpha subunit in Pichia pastoris

Analysis at the transcriptional level -- RNA was prepared from the transformants which scored positive after the genomic analysis. RNA was prepared using acid phenol. From each sample, 15 µg of RNA was loaded on a formaldehyde

agarose gel. After electrophoresis the RNA was blotted on a Hybond N membrane. The membrane was hybridizing using a radioactive probe, which consists of a 344 bp glucosidase II specific fragment, corresponding to the 3' region of the glucosidase II ORF. No signals were detected with non-transformed control strains, whereas clear signals were observed with transformants.

5

10

15

20

25

Analysis at the protein level using a double membrane assay -- A nitrocellulose membrane was placed on a buffered dextrose medium (BMDY). On top of that nitrocellulose membrane, a cellulose acetate membrane was placed. *Pichia* transformants of pGAPZAGLSII were streaked on the cellulose acetate and grown for a few days. The yeast cells remained on the cellulose acetate, while the secreted proteins crossed this membrane. As such the secreted protein was captured onto the nitrocellulose membrane. After a few days the cellulose acetate, containing the yeast colonies, was removed. The nitrocellulose membrane was analyzed for the presence of glucosidase II using anti-myc antibody. Most of the transformants gave a clear signal as compared to a faint, hardly visible signal with the WT, non-transformed strain.

Extracellular expression – PPY12-OH transformants of the construct pGAPZAGLSII(mychis6) (strains 12, 14 and 18) and transformants of the construct pGAPZAGLSII(myc)HDEL (strains H1, H2 and H3) were grown for 2 days on 2x10 ml BMDY medium. These 6 transformants earlier scored positive both on the genomic level (PCR on gDNA) and on the RNA level (Northern blot). The culture medium was collected by centrifugation and concentrated with Vivaspin columns to about 1 ml. Proteins from this concentrate were precipitated with TCA, resuspended in Laemmli buffer and loaded for SDS-PAGE analysis. Proteins were blotted to nitrocellulose membrane. The blot was incubated overnight with anti-myc Ab. The secondary Ab was linked to peroxidase. Using the Renaissance luminiscence detection kit (NEN) and a light sensitive film (Kodak), a strong band at about 110 kDa was observed for the transformants 12, 14 and 18, indicating that GLSII was expressed and secreted from these transformants. No signal was obtained for the transformants

5

10

15

25

H1-3, which indicate that the HDEL tag, which was added C-terminally to the GLSII ORF, resulted in an ER localization of the protein, preventing GLSII to be secreted into the growth medium.

Intracellular expression – The 6 transformants and the WT strain were grown for 2 days in 500 ml BMDY. The cells were collected by centrifugation, washed, resuspended into a minimal volume (50 mM Tris.HCl pH 7.5, 5% glycerol) and broken using glass beads. The cell debris was removed through several centrifugation steps (low speed centrifugation (2000-3000g)). Membranes were obtained from the supernatant through ultracentrifugation. The pellets were resuspended in Laemmli buffer and loaded for SDS-PAGE analysis. The proteins were blotted on a nitrocellulose membrane. The intracellular GLSII expression was checked using anti-myc Ab and peroxidase conjugated secondary Ab. Following the luminescence detection, a band at about 110 kDA was observed with the GLSIIHDEL tranformants (H1 and H3, faint signal for H2), but not with the WT and GLSII expression strains. These results clearly indicate the intracellular presence of the recombinant GLSII when expressed with a C-terminal HDEL tag. No GLSII was detected intracellularly when this tag was not present.

4.5 Purification and activity assays of the recombinant glucosidase II alpha 20 submit

A GLSII assay was set up as follows and was tested using a commercially available yeast alpha-glucosidase (Sigma) as a positive control.

Composition: 70 μ l 80 mM phosphate-citrate buffer pH 6.8, 7 μ l 250 mM mannose, 3.5 μ l 250 mM 2-deoxy-D-glucose, 0.8 μ l 4-MeUmbelliferyl-alpha-D-glucopyranoside (1 μ M). Three assays were performed: one with 1 unit commercial enzyme, one without the enzyme and one with the enzyme but without the substrate. The assay mixture was incubated overnight at 30°C. When illuminated with UV, only the reaction mixture with both the enzyme and the substrate showed fluorescence

(Figure 22). This indicates that the assay was very specific in detecting the activity of the alpha-glucosidase.

MT PPY12-OH, strain 18 and strain H3 were grown during 2 days in 2x10 ml growth medium. Cells were spun down and medium was adjusted to 300 mM NaCl and 10 mM imidazol and concentrated with Vivaspin columns to 0.5-1ml. Medium was loaded onto a Ni-NTA spin column (Qiagen) and the purification was performed according to the manufactures recommendations. Protein was eluted from the column in 2x100 μl elution buffer (50 mM NaH₂PO₄, 300 mM NaCl, 250 mM imidazol pH 8.0). From each eluate, 20 μl was assayed for its glucosidase II activity. 0.33 units of the commercial enzyme diluted in 20 μl of the elution buffer was used as a positive control. Fluorescence was observed with the positive control and the elute of strain 18, the strain which secreted the enzyme into the growth medium. These results indicate that the recombinant *S. cerevisiae* GLSII alpha subunit, secreted by *Pichia pastoris*, was a functionally active enzyme. The activity was not seen in the WT (untransformed) strain, nor in strain H3 as the GLSII was expressed intracellularly (**Figure 23**). These results also indicate that the beta subunit is not necessary for the functionality of the alpha part of the protein.

10

Example 5

Creating *Pichia* Strains Expressing both Glucosidase II and Mannosidase

5 Strain GS115 was transformed with pGAPZGLSII and pGAPZglsIIHDEL. Transformants were selected on YPDSzeo.

Strain yGC4 was transformed with the following constructs, respectively:

- (1) pGAPADEgIsII and pGAPADEgIsIIHDEL, selection on synthetic sorbitol medium without adenine;
 - (2) pGAPZMFManHDEL: selection on YPDSzeo; and
- (3) pGAPZMFManHDEL/pGAPADEglsIIHDEL: selection on synthetic sorbitol medium without adenine and with zeocin.

Strain yGC4 with OCH1 knock-in and expressing MFmannosidaseHDEL was transformed with pGAPADEglsII and pGAPADEglsIIHDEL. Selection of transformants was done on synthetic sorbitol medium without adenine and uracil.

For all transformations, colonies were obtained. Transformants with the expression vector(s) integrated into the genome, determined by PCR, were obtained. Expression of GLSII from some of these transformants was observed.

20

10

SEQUENCE LISTING

SEQ ID NO: 1 HDEL (peptide)

5

SEQ ID NO: 2

5'-GACTGGTTCCAATTGACAAGC-3'

SEQ ID NO: 3

5'-AGTCTAGATTACAACTCGTCGTGAGCAAGGTGGCCGCCCG TCG-3'

10 **SEQ ID NO: 4**

CCATTGAGGACGCATGCCGCGCC

SEQ ID NO: 5

GTATCTAGATTACAACTCGTCGTGCAGATCCTCTTCTGAGATGAGTTTTTGT

15 TCAGCAAGGTGGCCGCCCCGTCGTGATGAA

SEQ ID NO: 6

AACTCGAGATGGACTCTTCAAAACACAAACGC

20 **SEQ ID NO:** 7

TTGCGGCCGCTTACAACTCGTCGTGTCGGACAGCAGGATTACCTGA

SEQ ID NO: 8

CCATTGAGGACGCATGCCGCGCC

25

SEQ ID NO: 9

GCAAATGGCATTCTGACATCCT

SEQ ID NO: 10

30 GTCCCTATTTCAATCAATTGAA

SEQ ID NO:11

GACTGGTTCCAATTGACAAGC

35 **SEQ ID NO:12**

CCG CTC GAG ATG GTC CTT TTG AAA TGG CTC

SEQ ID NO:13

CCG GGC CCA AAA ATA ACT TCC CAA TCT TCAG

SEQ ID NO: 14

5

10

15

20

25

The ORF sequence of the MFManHDEL fusion in pGAPZMFManHDEL:

at gagatt teet tea attttta et get get tittatte geage at cete ege att aget get ce ag tea acaeta caa caga ag at gaar and a significant tittatte geage at cete ege att aget get cage to acaeta caa caga ag at gaar and a significant tittatte geage at cete ege att aget get cage to acaeta caa caga ag at gaar and a significant tittatte geage at cete ege att aget get cage to acaeta caa caga ag at gaar and a significant tittatte geage at cete ege att ag et get cage to acaeta caa caga ag at gaar and a significant tittatte geage at cete ege at the significant tittatte geage aacgg cacaa attccggctg aagctg tcatcggttactcag atttag aagggg atttcgatgttgctgttttgccattttccaacagcacaaataacgggttattgtttataaatactactattgccagcattgctgctaaagaagaaggggtatctctcgagaaaagag aggctgaagctgaattcgccacaaaacgtggatctcccaaccctacgagggcggcagcagtcaaggccgcattccagac gtcgtggaacgcttaccaccattttgcctttccccatgacgacctccacccggtcagcaacagctttgatgatgatgagaaacg getggggetcgtcggcaatcgatggettggacacggctatcctcatgggggatgccgacattgtgaacacgatccttcagtatgtaccg cag at caact tcaccac gactg cggttg ccaacca agg at cctccgtgttcg agaccaac attcgg tacctcggtggcctgctttctgcctatgacctgttgcgaggtcctttcagctccttggcgacaaaccagaccctggtaaacagccttctgag gcaggctcaaacactggccaacggctcaaggttgcgttcaccactcccagcggtgtcccggaccctaccgtcttcttcaac cctactgtccggagaagtggtgcatctagcaacaacgtcgctgaaattggaagcctggtgctcgagtggacacggttgagc gacctgacgggaaacccgcagtatgcccagcttgcgcagaagggcgagtcgtatctcctgaatccaaagggaagcccgg aggcatggcctggcctgattggaacgtttgtcagcacgagcaacggtacctttcaggatagcagcggcagctggtccggc ctcatggacagcttctacgagtacctgatcaagatgtacctgtacgacccggttgcgtttgcacactacaaggatcgctgggt cettggtgccgactcgaccattgggcatctcggctctcacccgtcgacgcgcaaggacttgacctttttgtcttcgtacaacg gacagtctacgtcgccaaactcaggacatttggccagttttggcggtggcaacttcatcttgggaggcattctcctgaacgag caaaagtacattgactttggaatcaagcttgccagctcgtactttggcacgtacacccagacggcttctggaatcggccccga aggettegegtgggtggacagegtgacgggegegegetegeegeetegteceagteegggttetactegteggea ggattetgggtgacggcaccgtattacatcctgcggccggagacgctggagagcttgtactacgcataccgcgtcacggg cgactccaagtggcaggacctggcgtgggaagcgttgagtgccattgaggacgcatgccgcgccggcagcgcgtactcg tecateaaegaegtgaegeaaeggeggggggggeetetgaegatatggagagettetggtttgeegaggegeteaa gtatgcgtacctgatctttgcggaggagtcggatgtgcaggtgcaggcaccggcgggaacaaatttgtctttaacacgga ggcgcacccctttagcatccgttcatcatcacgacggggcggccaccttgctcacgacgagttgtaa

SEQ ID NO: 15

The ORF sequence of the MFmManHDEL fusion in pGAPZMFmManHDEL:

30 atgagattteetteaatttttaetgetgttttattegeageateeteegeattagetgeteeagteaacactacaacagaagatgaa aeggeacaaatteeggetgaagetgteateggttaeteagatttagaaggggatttegatgttgetgttttgeeatttteeaaca

gcacaaataacgggttattgtttataaatactactattgccagcattgctgctaaagaaggagggtatctctcgagatggact ctt caa aa ac ac aa ac gett t gatet g g gett ag aa gat g t ta at teet cae g t ag at g ce g g caa ag g ag et aa aa ac ee comment of the second of the seconggcgtcttcctgatccatggacccgacgaacacagacacagggaagaagaagagcgtctgagaaataagattagagctg gaaaaacaaagtagcccaagcaatgaagacaaaagagaccagggtactgccgcctgtccctgtcccacaacgtgtaggg gtcagtggtggggatccagaagacatggagatcaagaagaaaagagacaaaattaaagagatgatgaaacatgcctggg ataattacagaacatacggatggggacataatgaactaaggcctattgcaaggaaaggccattccactaacatattcggaag atcctggctgagttcggcaccctgcacatggagtttgtgcacctcagctacttgaccggtgacttgacttactataataaggtc atgcacattcggaaactactgcagaaaatggaacgcccaaatggtctttatccaaattatttaaacccaagaacagggcgctg agaccacgaggcaagaaggatgtatgacgatgctgttgaggctatagaaaaacatcttattaagaagtcccgaggaggtct ggtttttattggagaatggaagaatggacaettggaaaggaagatggggcacttggcctgctttgctggggggaatgcttgcc cttggagcagatggttccagaaaggataaagctggccactacttagaactaggggcagaaattgcacgaacatgtcatgag tcatatgacagaactgcattgaaactaggtccggagtcattcaagtttgatggtgcagtggaagccgtggctgtgcggcagg ctgaaaagtattacatccttcgtccagaagtaattgaaacctattggtatctatggcgatttacccacgacccaagatacaggc agtggggctgggaagcactggctattgagaagtcgtgccgggtcagcggtgggttttctggtgtcaaggatgtatacg ccccgaccctgtgcatgacgacgtgcagcagagcttttctcttgctgaaacattaaaatacttgtacctgctgttctctggcga tgaccttctacctttagaccactgggtgtttaacacagaggcgcaccctctgccggtgttgcgcttagccaacagcactctttcaggtaatcctgctgtccgacacgacgagttgtaa

25 SEQ ID NO: 16 pAOX2ZAGLSII

10

15

20

gttegecetgegegaeeeggeggeaaetgegtgeaettegtggeegaggageaggaetgaeaegteegaeggeggee cacgggtcccaggcctcggagatccgtccccttttcctttgtcgatatcatgtaattagttatgtcacgcttacattcacgccct gaaggttttgggacgctcgaaggctttaatttgcaagctggagaccaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccctgacgagcatcacaaaaatcgacgctcaagtca gaggtggcgaaacccgacaggactataaagataccaggcgtttcccctggaagctccctcgtgcgctctcctgttccgac cetgeegettaceggatacetgteegeettteteecttegggaagegtggegettteteaatgeteaegetgtaggtateteagt tcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtat gtaggeggtgctacagagttcttgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgtgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcetttgatcttttctacggggtctgacgctcagtgga acgaaaactcacgttaagggattttggtcatgagatcagatcttttttcagaccatatgaccggtccatcttctacggggggat aaaaacatttactaaaaatcatacatcggcactctcaaacacgacagattgtgatcaagaagcagagacaatcaccactaag gttgcacatttgagccagtaggctcctaatagaggttcgatacttattttgataatacgacatattgtcttacctctgaatgtgtca atactetetegttettegtetegteagetaaaaatataaeaettegagtaagataegeeeaattgaaggetaegagataeeaga ctat cactag taga a cttt ga cat ct g cta a ag caga t ca a at a c cat ttat c caga at ca at ta c ctt c ctt tag ctt g t caga ag caga t ca at tac cat tag caga t ca at tag caga t ca at tac cat tag caga t ca at tag caga t caga tgcatgaaaaagctacatgaaaatccccatccttgaagttttgtcagcttaaaggactccatttcctaaaatttcaagcagtcctct caactaa att tttttccattcctctgcacccagccctcttcatcaaccgtccagccttctcaaaagtccaatgtaagtagcctgcaaattcaggttacaacccctcaattttccatccaagggcgatccttacaaagttaatatcgaacagcagagactaagcgagtcat cat cacca acca acgat g g t gaa aa a ctt taag cat ag att g at g g a g g t g t at g g cact t g g c g ct g cat t a g a g t t g a ct g cac t a g a g t t g a ct g cac t a g a g t t g a ct g cac t a g a g t t g a ct g cac t a g a g t t g a ct g a ct g cac t a g a g a ct gaactatggggtaatacatcacatccggaactgatccgactccgagatcatatgcaaagcacgtgatgtaccccgtaaactgc teggattategttgeaatteategtettaaacagtacaagaaactttatteatgggteattggactetgatgaggggcacatttee ccaatgattttttgggaaagaaagccgtaagaggacagttaagcgaaagagacaagacaacgaacagcaaaagtgacag aacaatgcaagttgataagacatcaccttccaagataggctatttttgtcgcataaatttttgtctcggagtgaaaaccccttttat gtgaacagattacagaagcgtcctacccttcaccggttgagatggggagaaaattaagcgatgaggagacgattattggtat

10

15

20

5

10

15

20

25

aaaagaagcaaccaaaatcccttattgtccttttctgatcagcatcaaagaatattgtcttaaaacgggcttttaactacattgttc ttacacattgcaaacctcttccttctatttcggatcaactgtattgactacattgatcttttttaacgaagtttacgacttactaaatcc a at gget c g tat geca at t gg tet tet ttace get ttt te geat ge gt ttace gae tat et at taa a gaa g t g t ge geat et g g t taken a geat general genertttgccatagaaacagggtttatgcagaaaatattgccaaatctcatcactgctattacaaagtggacgccgagtctattgcac acgate ctttag agaat g t gette at get accata at taa aactatae caa g at t g g ag g g g at g at at ag ce g t te ag t comment of the state of the stateattetetetetettttttacaggateacteagtaaggtteactataaatgagaaagagagaatgeeaaceaacagcageggtttg ttgatctcttcacaacggttcaatgagacctggaagtacgcattcgacaagaaatttcaagaggaggagaacaggaccagtattccacaattccacttccttaagcaaaaacaaactgtgaactcattctggtcgaaaatatcttcatttttgtcactttcaaactccac tgcagacacatttcatcttcgaaacggtgatgtatccgtagaaatctttgctgaaccttttcaattgaaagtttactggcaaaatg cgctgaaacttattgtaaacgagcaaaatttcctgaacattgaacatcatagaactaagcaggaaaacttcgcacacgtgctg ccagaagaaacaactttcaacatgtttaaggacaatttettgtattcaaagcatgactetatgcetttggggcetgaateggttg cgctagatttctctttcatgggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggctgatggacacttcagg cattcat gttttcatcttcgtccacatctatcttttgggtcaatgcagctgacacttgggtagacataaagtatgacaccagtaaaaataaaacgatgactcattggatctccgaaaatggtgtcatagatgtagtcatgtccctggggccagatattccaactatcattg acaaatttaccgatttgactggtagaccetttttaccgcccatttcctctatagggtaccatcaatgtagatggaattataatgatg gacaaaaaatattttacttggaagcagcactcctttcccaatccaaaaaggctgttatccaaattaaaaaagttgggtagaaat a caatggaa at gactat g taggt cattgct g g c caggt a attctat at g gatt gataccat a agcaa at at g g c caa a agatt tagge caa a gatt gataccat a g caa at a g cggaagtcctttttcgaacggtttatggatctgccggctgatttaactaatttattcatttggaatgatatgaacgagccttcgatttt cgatggcccagagaccacagctccaaaagatttgattcacgacaattacattgaggaaagatccgtccataacatatatggtc tatcagtgcatgaagctacttacgacgcaataaaatcgatttattcaccatccgataagcgtcctttccttctaacaagggcttttt ttgccggctctcaacgtactgctgccacatggactggtgacaatgtggccaattgggattacttaaagatttccattcctatggt tet g tea a a caa cat t g et g g t a t g c a t t t a t g g a g c e g a cat t g et g g g a t c t a ca c t g a a t t g a t g c t t g c g g a t c t a ca c t g a a t t g a t g c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c t g c g a c g a c g a c g a c g a c g a c g a c g a c g a c g a c c g a c gegttggtaccaagegggettatggtacccattttttagagcacaegeceatatagacaccaagagaagaaccatacttatt agtgtcactggatttccgataatgaatccaatgtttattgaacaccetgaatttgctgaattgtatcatatcgataaccaattttact

ggag ta att cag gt ctattag t caa acct gt cac ggag c ct gg t caat cag aa ac ggaa at gg ttt t c cac cc gg ta tatt ctattag to can be a considered and considered according to the considered accordingatttattgaaggcggtcacattatcactatgaaagataagtatagaagatcttcaatgttaatgaaaaacgatccatatgtaatag ttatagcccctgataccgagggacgagccgttggagatctttatgttgatgatggagaaacttttggctaccaaagaggtgag tacgtagaaactcagttcattttcgaaaacaataccttaaaaaaatgttcgaagtcatattcccgagaatttgacaggcattcacc acaatactttgaggaataccaatattgaaaaaatcattatcgcaaagaataatttacaacacaacataacgttgaaagacagtattaa agt caa aa aa aa ag g cgaa gaa ag tt catt g ccgac tag at cgt cat at gag aat gat aa taa gat cac catt cttaa cccatt cttategett gacataa ctgaag attggaag ttatttttgggeeegaacaaaa acteateteagaag ag gatetgaatag egeestateteagaag attggaag attggactatatagtataggatttttttttgtcattttgtttcttctgtacgagcttgctcctgatcagcctatctcgcagctgatgaatatcttgtcttcgtttgtgcggatcccccacacacatagcttcaaaatgtttctactccttttttactcttccagattttctcggactccgcgca tege eg tacca et teaaaa cacce aage acage at acta a att tte eet et tte et et ag g g t g teg tta att accegt actaa aggttt ggaaa agaaa aa aa agaccgect cgttt cttttt ctt cgt cgaaa aa aggcaat aa aa atttt tat cacgttt ctttt tcttttettgttetattaeaactttttttaettettgtteattagaaagaaageatageaatetaatetaagggeggtgttgaeaattaateatcggcatagtatatcggcatagtataatacgacaaggtgaggaactaaac

20 **SEQ ID NO: 17** pAOX2ADE1glsII

5

10

15

25

tegacegetgeattaatgaateggecaacgegggggagaggggtttgegtattgggegetetteegetteetegeteac tgactegetgegeteggteggegggageggtateageteacteaaaggeggtaataeggttatecacagaatea ggggataacgcaggaagaacatgtgagcaaaaggecagcaaaaggccaggaaccgtaaaaaggccggttgetgge gtttttecataggeteegeeceetgacgagcateacaaaaategacgeteaagteagaggtggegaaaccgacaggaat ataaagataccagggttteeceetggaageteeteetgtgegeteteetgtteegaceetgeggtaacetggatacetgteeg eettteteetteegggaagegggaggegetteeteetgtgegeteteetgtteeggtgaggtegttaeeggataeetgeeg gggetgtgtgaagagegggaggegetteeteetgtgaggtateteagtteggtgaggtegttegeteaaget gggetgtgtgaacgaaccccegtteageeegacegetgegeettateeggtaactategtettgagteeaacceggtaaga cacgacttategecactggcagcacctggtaacaggattaggagggaggtatgtaggeggtgetacagagttettg aagtggtggectaactaeggetacactagaaggacagtatttggtatetgegetetgetgaagccagttacetteggaaaaag

5

10

15

20

25

 $aaaaaggatctcaagaagatcctttgatcttttctacg \ gggtctgacgctcagtggaacgaaaactcacgttaagggattttgg$ cttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcac eggetecagatttateageaataaaceageeggaagggeegagegeagaagtggteetgeaaetttateegeeteea tccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacagg categt ggt gt caeget cgt tt ggt at gget te atteaget ce ggt te ceaaegat caa gge gagt ta cat gate ce category to be a considered and the considered at the cgcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgaga atagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtg ctcatcattggaaaacgttettcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgt gcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaa gggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatagctccaaggcaacaaattgactactcagac cgacattcattcgttattgattttaaatcaacgataaacggaatggttacttgaatgatttcactttatgatcattgtttactaattacc taaataggattttatatggaattggaagaataagggaaatttcagatgtctgaaaaaggcgaggagggtactaatcattcaag cccatttcttgccagtaattgcttcataagcttcaatatacttttctttactcttgatagcaatttctgcatccatggctacgccctctt tgccattcaatccgttggccgtcaaccaatctctgagaaactgcttatcgtaactctcttgcgatttacccacttggtaagtctttt gattccaaaatctagaagaatctggagttaaaacttcatctactagtaccaattcattgttttcgtccagtccaaattcgaatttcgt atcagcaataatgatccccttcaaaagggcgaagttttttgcagcagaatacaactcgaccgccttgacagcgaccttctcac aaatgtetttaeetaeaateteageagettgtteaatagagatgtttteategtgtteaeeetgtteagetttegttgaaggtgtgaa aatcggagttggaaaggcgtcgctctttgaaggttctcgttttcaaccttgactccatggacagtttttgagttcttgtactctttc catgcacttccagtgatgtaacctctgacaatggcttccaaaggtatcagtctgtgcttttttactatcaaggatcgtccctctaat tgagatttgtatttttetteagacagttttgatggtagtaaagcaaagactteettgteattagaagcaaccaaatgattetttatgta gggtgccaaaaaatcaaaccagaaaactgagagctgagtcaaaatctttcccttatcaggaataccgtttgtcataatcacatc gtaagcggagatacggtcagttgcgacgaacagcaagttgttctcatcgactgcataaatgtctctaacctttcctttggcgatt aaaggtaggattccgtccagatcagtgttcacaatggacatacttggaaggatacagcaaagtgtgttggaagcgatgacac atggaaaggaatttttegagttteetagagtagtatattggggeggtgaaagtteagatgtttaatgettaataetettataetette a a agegee cea agt g tttet gee a acct g actt ttt ttet g a at a at g at tea agt g agt at tt a a acc at g at ta agt ta eg to a acct g at ta agt ta ag

5

10

15

20

25

gatttggcactggataaggtcgaaaaatatccgtattcataaacgattattggtaaaagttacaaaataccactaattacggag aagettagtaacagttatcatctcttggtcgattaacgettacaatttccattcgccattcaggctgcgcaactgttgggaaggg ggagtgggaaataccaagaaaaacatcaaactcgaatgattttcccaaacccctaccacaagatattcatcagctgcgagat gtatcaaaaatgaagcetgcatctctcaggcaaatggcattctgacatcctcttgattagaatctagcaagaccggtcttctcgt aagtgcccaacttgaactgaggaacagtcatgtctaaggctaaaactcaatgatgatgatgatgatggtcgacggcgctattc agateetettetgagatgagtttttgttegggeecaaaaataaetteecaatetteagttatgteaagegataggttaagaatggt gatettattateatteteatatgaegatetagteggeaatgaaetttettegeeatttittttgaetttaataetgtettteaaegttatgt tgtgttgtaaattattetttgegataatgattttteaatattggtatteeteaaagtattgtggtgaatgeetgteaaattetegggaa tcatcaacataaagatetecaaeggetegteeeteggtateaggggetataaetattacatatggategtttttcattaacattga ctatcaaatcagtaccattgtttataaaagagtgtaaagatgcgaattcatagaatataccgggtgggaaaaccatttccgtttct gattgaccaggctccgtgacaggtttgactaatagacctgaattactccagtaaaattggttatcgatatgatacaattcagcaa cagga a at a tetra att gga ta at a tea ega et tea a aggit catt ga at a agt at ggt tet et et et eg te ta agga at a tea ega et e agga et e aagc cage tat g tegget ceta ta a at gge at accage a at gtt g tt gacaga accat agga a at gga a at cetta agt a at cetaga accat agga a at gga a at ggaaattggccacattgtcaccagtccatgtggcagcagtacgttggggggcagcagcagaaaaaagcccttgttagaaggaaaggac gettateggatggtgaataaategattttattgegtegtaagtagetteatgeaetgatagaceatatatgttatggaeggatettt ceteaatgtaattgtegtgaateaaatettttggagetgtggtetetgggecategaaaategaaggetegtteatateatteeaa atgaataaattagttaaatcagccggcagatccataaaccgttcgaaaaaggacttccaaatcttttggccatatttgcttatggt ateaatecatatagaattacetggceagcaatgacetacatagteattteeattgtgateettgaetgetacatttteattaattace etgteaetgattteataatetttetttaaatgaggategattagtaegaeaagatttetaeeeaaettttttaatttggataaeageet ga at catat gag cat ceatet gag ag te cat et gag a a c gae a teta ta tatat at te cat cat cat tatat gat gat accetat a tatat gat gag accetat gag accetagaggaaatgggcggtaaaaagggtctaccagtcaaatcggtaaatttgtcaatgatagttggaatatctggccccagggaca tgactacatctatgacaccattttcggagatccaatgagtcatcgttttatttttactggtgtcatactttatgtctacccaagtgtca

5

10

15

20

25

atgttgtactcaaagacatcaacgttgaaaagcctgtagggttcctttccacctgaagtgtccatcagccttagcgacgtcgca tgttccggtataccgtagacattagtagaacccatgaaagagaaatctagcgcaaccgattcaggccccaaaggcatagag tcatgctttgaatacaagaaattgtccttaaacatgttgaaagttgtttcttctggcagcacgtgtgcgaagttttcctgcttagttc tatgatgttcaatgttcaggaaattttgetcgtttacaataagtttcagcgcattttgccagtaaactttcaattgaaaaggttcagc aaagatttctacggatacatcaccgtttcgaagatgaaatgtgtctgcagtggagtttgaaagtgacaaaaatgaagatattttc gaccagaatgagttcacagtttgtttttgcttaaggaagtggaattgtggaatactggtcctgttcgcctcctcttgaaatttcttgt cgaatgegtacttecaggteteattgaacegttgtgaagagateaacaaacegetgetgttggttggcattetetttteteattt atagtgaacettactgagtgatectgtaaaaaagagagagagaatgggaactgaacggetatatcatcgccctccaatcttg gtatagttttaattatggtagcatgaagcacattctctaaaggatcgtgtgcaatagactcggcgtccactttgtaatagcagtg acgcatgcgaaaaagcggtaaagaagaccaattggcatacgagccatttcaaaaggaccatctcgaggtaccgatccgag atgtagtcaatacagttgatccgaaatagaaggaagaggtttgcaatgtgtaagaacaatgtagttaaaagcccgttttaagac aatattetttgatgetgateagaaaaggacaataagggattttggttgettettttataecaataategteteeteategettaatttt ctccccatctcaaccggtgaagggtaggacgcttctgtaatctgttcacataaaaggggttttcactccgagacaaaaatttat gegacaaaaatageetatettggaaggtgatgtettateaacttgeattgtttgeaaggagaageaaggacaaeteaacatgg gtaaaaattcaaaaccaaccaattggaaactcccaactgtccactaggtagctgacagctgtcacttttgctgttcgttgtcttgt ctctttcgcttaactgtcctcttacggctttctttcccaaaaaatcattggggaaatgtgcccctcatcagagtccaatgacccat gaataaagtttettgtaetgtttaagaegatgaattgeaacgataateegageagtttaeggggtaeateaegtgetttgeatat gatctcggagtcggatcagttccggatgtgatgtattaccccatagtttcaaactctaatgcagccgccaagtgccatacacc ctccatcaatctatgcttaaagtttttcaccatcgttgggtggtgatgatgactcgcttagtctgctgttcgatattaactttgtaa ggatcgcccttggatggaaaattgaggggttgtaacctgaatttgcaggctacttacattggacttttgagaaggctggacgg ttgatgaagagggctgggtgcagaggaatggaaaaaaatttagttgagaggactgcttgaaattttaggaaatggagtccttt aaatggatatttgatetgetttageagatgteaaagttetaetagtgatagtetggtatetegtageetteaattgggegtatetta ctcgaagtgttatatttttagctgacgagacgaagaacgagagatattgacacattcagaggtaagacaatatgtcgtattat caaaataagtategaacetetattaggageetactggeteaaatgtgeaacettagtggtgattgtetetgettettgateacaat

aacgtaaaagtgatttgaatcataaaagaatcaagatagaggtcaaagcatagataatccccccgtagaagatggaccggtcatatggtctgaaaaaaagatctgatctcatg

SEQ ID NO: 18 pGAPZAGLSII

5

10

15

20

25

gtgtgcgcaatctgggttttgccatagaaacagggtttatgcagaaaatattgccaaatctcatcactgctattacaaagtgga cgccgagtctattgcacacgatcctttagagaatgtgcttcatgctaccataattaaaactataccaagattggagggcgatga tatagccgttcagttcccattctctctctctttttacaggatcactcagtaaggttcactataaatgagaaagagagaatgccaa ccaacagcagcggtttgttgatctcttcacaacggttcaatgagacctggaagtacgcattcgacaagaaatttcaagagga ttgtcactttcaaactccactgcagacacatttcatcttcgaaacggtgatgtatccgtagaaatctttgctgaaccttttcaattg aaagtttactggcaaaatgcgctgaaacttattgtaaacgagcaaaatttcctgaacattgaacatcatagaactaagcagga a a act tegea caegt get ge caga a aga a acatt tea acat gtt ta agga ca at ttet t g ta t ca ag cat gaet et a get ta again to the catter of thetggggcctgaatcggttgcgctagatttctctttcatgggttctactaatgtctacggtataccggaacatgcgacgtcgctaag getgatggacaetteaggtggaaaggaaccetacaggetttteaacgttgatgtetttgagtacaacateggtaccagceaac agtatgacaccagtaaaaataaaacgatgactcattggatctccgaaaatggtgtcatagatgtagtcatgtccctgggggcca gatattccaactatcattgacaaatttaccgatttgactggtagaccctttttaccgcccatttcctctatagggtaccatcaatgta gatggaattataatgatgagatggacgttetcacagtggactetcagatggatgetcatatgatteettacgattttatttggttgg acttggagtatacgaacgacaaaaatattttacttggaagcagcactcctttcccaatccaaaaggctgttatccaaattaaa aaagttgggtagaaatettgtegtactaategateeteatttaaagaaagattatgaaateagtgacagggtaattaatgaaaat gtagcagtcaaggatcacaatggaaatgactatgtaggtcattgctggccaggtaattctatatggattgataccataagcaaa tatggccaaaagatttggaagtcctttttcgaacggtttatggatctgccggctgatttaactaatttattcatttggaatgatatga acgage et tegatt tegat tegat gecea gagace acage tecaa aag at ttgatte acgae a attacatt gaggaa ag at ceg tegat tegcataacatatatggtctatcagtgcatgaagctacttacgacgcaataaaatcgatttattcaccatccgataagcgtcctttcct tetaacaagggetttttttgccggeteteaacgtactgetgecacatggactggtgacaatgtggecaattgggattacttaaag acctgaattgattgcacgttggtaccaagcgggcttatggtacccattttttagagcacacgcccatatagacaccaagagaa gagaaccatacttattcaatgaacctttgaagtcgatagtacgtgatattatccaattgagatatttcctgctaccttataca

5

10

15

20

25

ccat gttt cata a at caa gt gt cact gg at ttcc gat a at ga at cca at gttt at t ga a caccet ga at tt get ga at t gt at cat at get ga at the control of the cccaccegg tatattctatga attege at ctttataa acaatgg tactgatttgataga aa agaa tatttctg caccattggataaaa attccattatttattgaaggcggtcacattatcactatgaaagataagtatagaagatcttcaatgttaatgaaaaacgatccatatgtaatagttatagcccctgataccgagggacgagccgttggagatctttatgttgatgatggagaaacttttggct accaaagaggtgagtacgtagaaactcagttcattttcgaaaacaataccttaaaaaatgttcgaagtcatattcccgagaattt gacaggcattcaccacaatactttgaggaataccaatattgaaaaaatcattatcgcaaagaataatttacaacacaacataac gttgaaagacagtattaaagtcaaaaaaaatggcgaagaaagttcattgccgactagatcgtcatatgagaatgataataaga teaceattettaacetategettgacataactgaagattgggaagttatttttgggcccgaacaaaaactcatetcagaagagg atetgaatagegeegtegaceateateateateateatgagttttageettagacatgaetgtteeteagtteaagttgggeact tacgagaagaccggtcttgctagattctaatcaagaggatgtcagaatgccatttgcctgagagatgcaggcttcatttttgataettttttatttgtaacetatatagtataggattttttttgteattttgttettetegtaegagettgeteetgateageetatetegeaget gatgaatatctt gtggtaggggtttgggaaaat cattcg ag ttt gatgtttttctt ggtatttcccactcctcttcag ag tacagaagattaagtgagacettegtttgtgeggateeeeeacacacatagetteaaaatgtttetaeteettttttaetetteeagattttete acgtttcttttcttgaaatttttttttttttagtttttttctctttcagtgacctccattgatatttaagttaataaacggtcttcaatttctcaa tgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaactaaaccatggccaagttgaccagtg gtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtgccggacaacaccetggcetgggtgtgggtgcgcggcetggacgagetgtacgccgagtggtcggaggtcgtgtccacgaacttc ceggeaactgegtgeacttegtggeegaggaggaggactgacaegteegaeggeggeecaegggteeeaggeetegga gatecgteecectttteetttgtegatateatgtaattagttatgteaegettaeatteaegeceteececeaeateegetetaaeeaatttttetttttttetgtacagaegegtgtaegeatgtaacattataetgaaaacettgettgagaaggttttgggaegetegaa ggetttaatttgeaagetggagaceaacatgtgageaaaaggeeageaaaaggeeaggaacegtaaaaaggeegegttg ctggcgtttttccataggctccgccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgaca

SEQ ID NO: 19 pGAPADE1glsII

5

10

15

20

25

ccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcac cggctccagatttatcagcaataaaccagccagccggaagggccgagcagaagtggtcctgcaactttatccgcctcca tccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcateg tgg tg teacgeteg tegt tgg tatgg ette atteageteegg tteeceaa egateaa ggeg ag ttaeat gateece categories.geageaetgeataattetettaetgteatgeeateegtaagatgettttetgtgaetggtgagtaeteaaeeaagteattetgaga atagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtg ctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgt gcacceaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaa gggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatagctccaaggcaacaaattgactactcagac cgacattcattcgttattgattttaaatcaacgataaacggaatggttacttgaatgatttcactttatgatcattgtttactaattacc taaataggattttatatggaattggaagaataagggaaatttcagatgtctgaaaaaggcgaggggggtactaatcattcaag cccatttcttgccagtaattgcttcataagcttcaatatacttttctttactcttgatagcaatttctgcatccatggctacgccctctt tgccattcaatccgttggccgtcaaccaatctctgagaaactgcttatcgtaactctcttgcgatttacccacttggtaagtctttt gattccaaaatctagaagaatctggagttaaaacttcatctactagtaccaattcattgttttcgtccagtccaaattcgaatttcgt atcagcaataatgatccccttcaaaagggcgaagttttttgcagcagaatacaactcgaccgccttgacagcgaccttctcac aaatgtetttaeetaeaateteageagettgtteaatagagatgtttteategtgtteaeeetgtteagetttegttgaaggtgtgaa aateggagttggaaaggegtegetetettgaaggttetegtttteaacettgaeteeatggaeagtttttgagttettgtaetettte catgca cttc cag tgat gtaacctct gacaat ggette caa ag gtat cag tet gt gett ttttact at caa ggat cgteet ctaattgagatttgtatttttetteagacagttttgatggtagtaaagcaaagactteettgteattagaagcaaccaaatgattetttatgta gggtgccaaaaaatcaaaccagaaaactgagagctgagtcaaaatctttcccttatcaggaataccgtttgtcataatcacatc gtaageggagataeggteagttgegaegaaeageaagttgtteteategaetgeataaatgtetetaaeettteetttggegatt aaaggtaggatteegteeagateagtgtteacaatggacatacttggaaggatacagcaaagtgtgttggaagegatgacac atggaaaggaatttttcgagtttcctagagtagtatattggggcggtgaaagttcagatgtttaatgcttaatactcttctcaaagcgcccaagtgtttctgccaacctgacttttttctgaataatgaatcgttcaagtggagtatttaaaccatgattaagttacgt gatttggcactggataaggtcgaaaaatatccgtattcataaacgattattggtaaaagttacaaaataccactaattacggag aagettagtaacagttatcatctcttggtcgattaacgettacaatttccattcgccattcaggctgcgcaactgttgggaaggg cgateggtgegggeetettegetattaegeeagggeetegaggeacaaaegaaegteteaettaatettetgtaetetgaaga ggagtgggaaataccaagaaaaacatcaaactcgaatgattttcccaaacccctaccacaagatattcatcagctgcgagat

5

10

15

20

25

gtatcaaaaatgaagcetgcatctctcaggcaaatggcattctgacatcctcttgattagaatctagcaagaccggtcttctcgt aagtgcccaacttgaactgaggaacagtcatgtctaaggctaaaactcaatgatgatgatgatggtggtcgacggcgctattc agatect cttct gagat gagttttt gttcgggcccaaaaat aact teccaatet teagt tat gtcaage gatag gttaagaat ggtaagat gagat gagatettattateatteteatatgaegatetagteggeaatgaaetttettegeeatttttttgaetttaataetgtettteaaegttatgttgtgttgtaaattattctttgcgataatgattttttcaatattggtattcctcaaagtattgtggtgaatgcctgtcaaattctcgggaa tatgacttcgaacattttttaaggtattgttttcgaaaatgaactgagtttctacgtactcacctctttggtagccaaaagtttctcca teateaacataaagateteeaacggetegteeteggtateaggggetataactattacatatggategttttteattaacattga agatct tetatact tatett teatagt gataat gt gacegeet teaataa at aat ggaatt ttatee aat ggt geagaa at attett ttatee aat ggt geagaa at gata te tatet gataat gatactatcaaatcagtaccattgtttataaaagagtgtaaagatgcgaattcatagaatataccgggtgggaaaaccatttccgtttct gattgaccaggctccgtgacaggtttgactaatagacctgaattactccagtaaaattggttatcgatatgatacaattcagcaa caggaaatateteaattggataatateacgtactategaetteaaaggtteattgaataagtatggttetettetettggtgtetata agccagctatgtcggctcctataaatggcataccagcaatgttgtttgacagaaccataggaatggaaatctttaagtaatccc gettateggatggtgaataaategattttattgegtegtaagtagetteatgeaetgatagaeeatatatgttatggaeggatetttcetcaatgtaattgtcgtgaatcaaatettttggagetgtgtctctgggccatcgaaaatcgaaggetcgttcatatcattccaa at gaataa at tagttaa at cag ccg gcag at ccataa accgt tcgaa aa ag gact tcca aat cttt t gg ccat at tt gct tat gg tagt and tagt tagt at gas a consideration of the consideration octg t cactg at the attack the titta a at gaggate gattagt accase a gatter to access a continuous access and the tittal attack the tittal and the tittal access and the tittal access access access and the tittal access access access and the tittal access accga at catat gag ag accetet gag ag accete tatat at the cateta cat tata at the cateta cat tata gat gag the cateta at the cateta catetagaggaaatgggcggtaaaaagggtctaccagtcaaatcggtaaatttgtcaatgatagttggaatatctggccccagggaca tgactacatctatgacaccattttcggagatccaatgagtcatcgttttatttttactggtgtcatactttatgtctacccaagtgtca atgttgtactcaaagacatcaacgttgaaaagcctgtagggttcctttccacctgaagtgtccatcagccttagcgacgtcgca tgttccggtataccgtagacattagtagaacccatgaaagagaaatctagcgcaaccgattcaggccccaaaggcatagag

SEQ ID NO: 20 pPICZAGLSII

5

10

15

20

25

ggcgggagttcgccctgcgcgacccggccagctacttcgtgcacttcgtggccgaggagcaggactgacacgtccgac ggcggcccacgggtcccaggcctcggagatccgtccccttttcctttgtcgatatcatgtaattagttatgtcacgcttacattttgcttgagaaggttttgggacgctcgaaggctttaatttgcaagctggagaccaacatgtgagcaaaaggccagcaaaag gccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgccccctgacgagcatcacaaaaatcgacgc tcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcct gtteegaceetgeegettaeeggataeetgteegeettteteeettegggaagegtggegettteteaatgeteaegetgtagg tatct cagt toggt tagg tog ttogct coaget tgg get tgt g tage acces cagt teage cog accept tage to the tage toggt tagget the tage to tage the tage toggt tagget taggecgg taactatcg tcttg ag tccaaccegg taag acac gacttatcg ccactgg cag cag cactgg taac ag gattag caggegetetgetgaagecagttacetteggaaaaagagttggtagetettgateeggeaaacaaaceaeegetggtageggtg ttttgccatccgacatccacaggtccattctcacacataagtgccaaacgcaacaggaggggatacactagcagcagaccg ttgeaaaegeaggaceteeaeteetetteteeteaaeaeeeaettttgeeategaaaaaeeageeeagttattgggettgattg gageteget cattee a atteet tetat tagget a ctaacaccat gaett tattage et get catteet ggeece cet ggegaggt team of the contract ofatgtttgtttattteegaatgeaaeaageteegeattaeaeeegaaeateaeteeagatgagggetttetgagtgtggggteaa atagtttcatgttccccaaatggcccaaaactgacagtttaaacgctgtcttggaacctaatatgacaaaagcgtgatctcatcc aagatgaactaagtttggttcgttgaaatgctaacggccagttggtcaaaaagaaacttccaaaagtcggcataccgtttgtct tgtttggtattgattgacgaatgctcaaaaataatctcattaatgcttagcgcagtctctctatcgcttctgaaccccggtgcacct gtgccgaaacgcaaatggggaaacacccgctttttggatgattatgcattgtctccacattgtatgcttccaagattctggtgg gaatactgetgatagcetaacgtteatgateaaaatttaactgttetaacccctacttgacagcaatatataaacagaaggaag ctgccctgtcttaaacctttttttttatcatcattattagcttactttcataattgcgactggttccaattgacaagcttttgattttaacg gateggtacetegagatggteettttgaaatggetegtatgeeaattggtettetttacegetttttegeatgegtttacegaetat ctattaaagaagtgtgcgcaatctgggttttgccatagaaacagggtttatgcagaaaatattgccaaatctcatcactgctatt

5

10

15

20

25

acaaagtggacgccgagtctattgcacacgatcctttagagaatgtgcttcatgctaccataattaaaactataccaagattgg agggcgatgatatagccgttcagttcccattctctctcttttttacaggatcactcagtaaggttcactataaatgagaaagag aga at gecaac caa cag cag c g st t g at ctet t caca acg g t t caat g aga act g g a ag t acg cat t c g acaa g a a at t considerable and the considerable according to the considerable accttttcaattgaaagtttactggcaaaatgcgctgaaacttattgtaaacgagcaaaatttcctgaacattgaacatcatagaact aagcaggaaaacttegcacacgtgctgccagaagaaacaactttcaacatgtttaaggacaatttcttgtattcaaagcatga ctctatgcctttggggcctgaatcggttgcgctagatttctctttcatgggttctactaatgtctacggtataccggaacatgcga egtegetaaggetgatggacactteaggtggaaaggaaccetacaggetttteaacgttgatgtetttgagtacaacateggt accagecaaccaatgtaeggttegateceatteatgtttteatettegteeacatetatettttgggteaatgeagetgaeacttg ggtagacataaagtatgacaccagtaaaaataaaacgatgactcattggatctccgaaaatggtgtcatagatgtagtcatgtccctggggccagatattccaactatcattgacaaatttaccgatttgactggtagaccctttttaccgcccatttcctctataggg taccatcaatgtagatggaattataatgatgagatggacgttetcacagtggactetcagatggatgetcatatgattecttacg attttatttggttggacttggagtatacgaacgacaaaaaatattttacttggaagcagcactcctttcccaatccaaaaaggctg aattaatgaaaatgtagcagtcaaggatcacaatggaaatgactatgtaggtcattgctggccaggtaattctatatggattgat accata agca a at atggcca a aggatt tgg a agt cett ttt cga acggt tatggat ctgccggct gat tta act a att att catter a consideration of the consideration of thetggaatgatatgaacgagcettcgattttcgatggcccagagaccacagctccaaaagatttgattcacgacaattacattga ggaaagatccgtccataacatatatggtctatcagtgcatgaagctacttacgacgcaataaaatcgatttattcaccatccgat aagegteettteettetaacaagggetttttttgeeggeteteaaegtaetgetgeeaeatggaetggtgaeaatgtggeeaatt gggattacttaaagatttccattcctatggttctgtcaaacaacattgctggtatgccatttataggagccgacatagctggcttt getgaggateetacacetgaattgattgeaegttggtaceaagegggettatggtacecattttttagageaeaegeeeatata gacaccaagagaagaaccatacttattcaatgaacctttgaagtcgatagtacgtgatattatccaattgagatatttcctgc tacctaccttatacaccatgtttcataaatcaagtgtcactggatttccgataatgaatccaatgtttattgaacaccctgaatttgc tgaattgtatcatatcgataaccaattttactggagtaattcaggtctattagtcaaacctgtcacggagcctggtcaatcagaaa cggaaatggttttcccacccggtatattctatgaattcgcatctttacactcttttataaacaatggtactgatttgatagaaaagaatatttetgeaceattggataaaatteeattatttattgaaggeggteacattateactatgaaagataagtatagaagatetteaa tgttaatgaaaaacgatccatatgtaatagttatagcccctgataccgagggacgagccgttggagatctttatgttgatgatg gagaaacttttggctaccaaagaggtgagtacgtagaaactcagttcattttcgaaaacaataccttaaaaaatgttcgaagtc

5 **SEQ ID NO: 21** pPICADE1glsII

10

15

20

25

gt caagtagggt tagaa cagttaaattttgat catgaa cgt taggct at cagcagt at tee caccagaa tett ggaag catae can be a common of the commoaatgtggagacaatgcataatcatccaaaaagcgggtgtttccccatttgcgtttcggcacaggtgcaccggggttcagaag atattaggttccaagacagcgtttaaactgtcagttttgggccatttggggaacatgaaactatttgaccccacactcagaaag aactgggctggtttttcgatggcaaaagtgggtgttgaggagaagaggagtggaggtcctgcgtttgcaacggtctgctgct cegetteetegeteactgaetegeteggteggteggteggegggggggtateageteacteaaaggeggtaataeg gttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaa ggcegcgttgctggcgtttttccataggctccgccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcg a a accega cagga ctata a agata c cagge gtttccccet gga aget ceet egt geget ctcct gttccga ccet geeget the control of the contraccggatacct gtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaacccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttga gtgctacagagttcttgaagtggtggctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagcca gttacetteggaaaaagagttggtagetettgateeggeaaacaaaceaeegetggtageggtggtttttttgtttgcaageag aagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatc

5

10

15

20

25

catagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccg ttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactca accaagtcattctgagaatagtgtatgcggcgaccgagttgetettgcccggcgtcaatacgggataataccgcgccacata gcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaagge aaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatagctccaaggcaac aaattgactactcagaccgacattcattcgttattgattttaaatcaacgataaacggaatggttacttgaatgatttcactttatga tcattgtttactaattacctaaataggattttatatggaattggaagaataagggaaatttcagatgtctgaaaaaaggcgaggag ggtactaatcattcaagcccatttcttgccagtaattgcttcataagcttcaatatacttttctttactcttgatagcaatttctgcatc catggctacgccctctttgccattcaatccgttggccgtcaaccaatctctgagaaactgcttatcgtaactctcttgcgatttac ccacttggtaagtcttttgattccaaaatctagaagaatctggagttaaaacttcatctactagtaccaattcattgttttcgtccag tecaaattegaatttegtateageaataatgateeeetteaaaagggegaagttttttgeageagaataeaaetegaeegeettg acagegacetteleacaaatgtetttacetacaateteageagettgtteaatagagatgtttteategtgtteaceetgtteaget ttegttgaaggtgtgaaaateggagttggaaaggegtegetetettgaaggttetegtttteaacettgaeteeatggaeagtttt tgagttettgtaetettteeatgeaetteeagtgatgtaaeetetgacaatggetteeaaaggtateagtetgtgettttttaetatea cgtttgtcataatcacatcgtaagcggagatacggtcagttgcgacgaacagcaagttgttctcatcgactgcataaatgtctc taacctttcctttggcgattaaaggtaggattccgtccagatcagtgttcacaatggacatacttggaaggatacagcaaagtg cttaatactcttatactcttcaaagcgcccaagtgtttctgccaacctgacttttttctgaataatgaatcgttcaagtggagtattta aaccatgattaagttacgtgatttggcactggataaggtcgaaaaatatccgtattcataaacgattattggtaaaagttacaaa at accact a attacg gaga agett agta a cagt tat catct cttgg tegatt aa egett acaatt tee attege catte agget geat ctt ctg tactet gaag ag gag t gg gaaa taccaa gaaa aa aa catcaa acte gaat gat ttt cccaa accect accacaa gat acceptance of the companion of t

caagaccggtcttctcgtaagtgcccaacttgaactgaggaacagtcatgtctaaggctacaaactcaatgatgatgatgatg atggtcgacggcgctattcagatcctcttctgagatgagtttttgttcgggcccaaaaataacttcccaatcttcagttatgtcaa gcctgtcaaattctcgggaatatgacttcgaacattttttaaggtattgttttcgaaaatgaactgagtttctacgtactcacctcttt ggtagccaaaagtttctccatcatcaacataaagatctccaacggctcgtccctcggtatcaggggctataactattacatatg atggtg cagaa at attettte tatea aateag taccattgtt tataa aagagtg taaagatg cgaatte atagaa tataccgggtgggaaaaccatttccgtttctgattgaccaggctccgtgacaggtttgactaatagacctgaattactccagtaaaattggttat cgatatgatacaattcagcaaattcagggtgttcaataaacattggattcattatcggaaatccagtgacacttgatttatgaaac atggtgtataaggtagcaggaaatatctcaattggataatatcacgtactatcgacttcaaaggttcattgaataagtatg ggtgtaggatcctcagcaaagccagctatgtcggctcctataaatggcataccagcaatgttgtttgacagaaccataggaat cttgttagaaggaaggacgcttatcggatggtgaataaatcgattttattgcgtcgtaagtagcttcatgcactgatagaccatatatgttatggacggatctttcctcaatgtaattgtcgtgaatcaaatcttttggagctgtggtctctgggccatcgaaaatcgaa ggetegtteatateatteeaaatgaataaattagttaaateageeggeagateeataaacegttegaaaaaggaetteeaaate ttttggccatatttgcttatggtatcaatccatatagaattacctggccagcaatgacctacatagtcatttccattgtgatccttga caaccaaataaaategtaaggaateatatgageateeatetgagagteeaetgtgagaaegteeateteateattataatteeat ctacattgatggtaccctatagaggaaatgggcggtaaaaagggtctaccagtcaaatcggtaaatttgtcaatgatagttgg a at at ctggccccagggacatgactacatct at gacaccattt tcggagatcca at gagtcatcgtt ttattt tactggtgtcatatacattggttggctggtaccgatgttgtactcaaagacatcaacgttgaaaagcctgtagggttcctttccacctgaagtgtcca teageettagegaegtegeatgtteeggtataeegtagaeattagtagaaeceatgaaagagaaatetagegeaaeegatte aggccccaaaggcatagagtcatgctttgaatacaagaaattgtccttaaacatgttgaaagttgtttcttctggcagcacgtgt

10

15

20

gcgaagtttteetgcttagttetatgatgtteaatgtteaggaaattttgetegtttacaataagttteagegcattttgecagtaaa cttteaattgaaaaggtteageaaagatttetaeggatacateacegtttegaagatgaaatgtgtetgeagtggagtttgaaag tgacaaaaaatgaagatattttegaceagaatgagtteacagtttgtttttgettaaggaagtggaattgtggaataetggteetgt tegeeteetettgaaatttettgtegaatgegtaetteeaggteteattgaaeegttgtgaagagateaacaaacegetgetgttg gttggcatteetettteteatttatagtgaacettaetgagtgateetgtaaaaaagagagagagagaatgggaaetgaaeggeta tateategeeeteeaatettggtatagttttaattatggtageatgaageacatteetaaaggategtgeaatagaeteggeg teeaetttgtaatageagtgatggaattggeaatattttetgeataaaceetgtttetatggeaaaaeceagattgegeaeaett etttaatagatagteggtaaaegeatgegaaaaaggggtaaaggaceattetetaaaggaeeattteaaaaggaeeatteettaaaaggaeeatteetaaaaggaeeatteettaaaaggaeeaett etttaatagatagteggtaaaegeatgegaaaaageggtaaagaagaeeattggeataegageeattteaaaaggaeeatteeg

10 **SEQ ID NO: 22** pYPT1ZAGLSII

5

15

20

25

cgaacaaaaactcatctcagaagaggatctgaatagcgccgtcgaccatcatcatcatcatcattgagtttgtagccttagac at gact gttcct cagt tca agt tggg cact tac gag aa gac cgg tctt gct ag att cta at caa gag gat gt cag aat gcc att the state of the stategettgeteetgateageetatetegeagetgatgaatatettgtggtaggggtttgggaaaateattegagtttgatgtttttettg gtatttcccactcctcttcagagtacagaagattaagtgagaccttcgtttgtgcggatcccccacacaccatagettcaaaatg ttte tacte et tttta actetic cag at ttte tegga et eege geatege eg tacea et teaaaa acae ceaa geata et aan ttte tactetic total en tegga et eege geatege eg tacea et teaaaa acae ceaa geata et aan ttte tactetic tegga et eege geatege eg tacea et teaaaa acae ceaa geata et aan tegga et eege geatege eg tacea et teaaaa eacae ceaa geata et aan teges eg tacea et teaaaa et teaaaa et teaaaa eacae et teaaaa et teaaaaa et teaaaa et teaaaaa et teaaaa et teaaaaa et teaaaa et teaaaa et teaaaa et teaaaa et teaaaa et teaaaaa et teaaaa et teatttteeetettetteetetagggtgtegttaattaeeegtaetaaaggtttggaaaagaaaaaagagaeegeetegtttettttte gcatagcaatctaatctaagggggggtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgag ccgaccggctcgggttctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcaggegggagttegeeetgeggaeeeggeaactgegtgeaettegtggeegaggageaggaetgaeaegteegae ggcggcccacgggtcccaggcctcggagatccgtccccttttcctttgtcgatatcatgtaattagttatgtcacgcttacatt

5

10

15

20

25

gccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgccccctgacgagcatcacaaaaatcgacgc tcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcct gttccgaccetgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcaatgctcacgctgtagg tateteagtteggtgtaggtegttegeteeaagetgggetgtgtgeaegaaeeeeeegtteageeegaeegetgegettate eggtaactategtettgagteeaaceeggtaagacaegaettategeeactggeageageeactggtaacaggattageag agcgagg tatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgc tcagtggaacgaaactcacgttaagggattttggtcatgagatcagatctatgatgagtcacaatctgcttccacagacgagt acaaggacaggcaaaaggaattggaagaagttgctaacccaataatgagcaagttctatggagctgctggtggagctcctg gtggagetectggtggettecetggaggtttecetggeggagetggegcagetggeggtgeeeeaggtggtgetgeeeea aggaa atta aggaa attttggatcta ata at gtgctgtatgccgacatcgggcatcgtagattgtatagtatcgctgacactataataagccagccaaaacccctaaaccagttgccctccactaattagtgtactacccaatcttgcctcttcgggtgtcttttataag gacagattcacaagctcttgttgcccaatacacacatacacagagataatagcagtcgaattcacgtggcccagccggc cgtctcggatcggtacctcgagatggtccttttgaaatggctcgtatgccaattggtcttctttaccgctttttcgcatgcgtttac cgactatetattaaagaagtgtgegeaatetgggttttgecatagaaacagggtttatgeagaaaatattgecaaateteateac tgct attaca a agtggacgccg agtct attgcacacgat cett tagaga attgtgctt cat gct accata atta aa actatacca agtggacgccg agtct attgcacacgat cett tagaga attgtgct to a transfer of the control ofaaagagagaatgccaaccaacagcagcggtttgttgatctcttcacaacggttcaatgagacctggaagtacgcattcgaca tegaaaatatetteatttttgteaettteaaacteeaetgeagaeaeattteatettegaaaeggtgatgtateegtagaaatetttg ctgaaccttttcaattgaaagtttactggcaaaatgcgctgaaacttattgtaaacgagcaaaatttcctgaacattgaacatcat agaactaagcaggaaaacttcgcacacgtgctgccagaagaaacaactttcaacatgtttaaggacaatttcttgtattcaaa gcatgactctatgcctttggggcctgaatcggttgcgctagatttctctttcatgggttctactaatgtctacggtataccggaac atgcgacgtcgctaaggctgatggacacttcaggtggaaaggaaccctacaggcttttcaacgttgatgtctttgagtacaac ateggtaecagecaaccaatgtaeggttegateceatteatgtttteatettegteeaeatetatettttgggteaatgeagetga

tcatgtccctggggccagatattccaactatcattgacaaatttaccgatttgactggtagaccctttttaccgcccatttcctcta ttacgattttatttggttggacttggagtatacgaacgacaaaaaatattttacttggaagcagcactcctttcccaatccaaaaa attgataccataagcaaatatggccaaaagatttggaagtcctttttcgaacggtttatggatctgccggctgatttaactaattta tt catttgga at gaac gag cott cgatttt cgat gg ccca gag ac caca gct ccaa aa gattt gatt cac gac aat tacattgaggaaagatccgtccataacatatatggtctatcagtgcatgaagctacttacgacgcaataaaatcgatttattcaccat ccgataagcgtcctttccttctaacaagggctttttttgccggctctcaacgtactgctgccacatggactggtgacaatgtggc ca attggg attact ta a agatttc cattcct at ggttctgtca a a cattgctgg tatgcc atttat aggagccga cat agetgg attact tataggagccga cattgctg to the control of the cogctttgctgaggatcctacacctgaattgattgcacgttggtaccaagcgggcttatggtacccattttttagagcacacgccc atatagacaccaagagaagaaccatacttattcaatgaacctttgaagtcgatagtacgtgatattatccaattgagatattt cetgctacetacettatacaccatgtttcataaatcaagtgtcactggatttccgataatgaatccaatgtttattgaacaccctga agaa acggaa atggttttcccacccgg tatattctat gaattcgcatctttacactcttttataaacaatggtactgatttgatagactt caat g taat g aaaaac g at ccatat g taat a g ttatag cccct g at a ccg ag g g ac g ag ccg tt g g ag at ctt tat g tt g a g ac g ag g ac g ag ac g actgatggagaaacttttggctaccaaagaggtgagtacgtagaaactcagttcattttcgaaaacaataccttaaaaaatgttcg aagtcatattcccgagaatttgacaggcattcaccacaatactttgaggaataccaatattgaaaaaatcattatcgcaaagaat at at gaga at gata at a a gat caccattct ta acctate gett gacata act gaa gat t ggga a g tt at ttt t gggcc

SEQ ID NO: 23 pYPT1ADE1glsII

5

10

15

20

5

10

15

20

25

tgggctgtgtgcacgacccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaag gaagtggtggctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaa aaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttgcccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctca ccggctccagatttatcagcaataaaccagccagcaggaagggccgagcagaagtggtcctgcaactttatccgcctccggcagcactgcataattetettactgtcatgccatccgtaagatgettttetgtgactggtgagtaetcaaccaagtcattetgag get cat cattggaaaa acgt tetteggggegaaaa actetea aggatetta ee get gttgagatee agttegatgta acceae tegen aggatet acceae tegen get acceae tegen gtgcacccaactgatettcagcatettttaettteaccagegtttetgggtgagcaaaaacaggaaggcaaaatgccgcaaaaa agggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatagctccaaggcaacaaattgactactcaga ctaaataggattttatatggaattggaagaataagggaaatttcagatgtctgaaaaaggcgaggagggtactaatcattcaa geceatttettgecagtaattgetteataagetteaatataettttetttaetettgatageaatttetgeateeatggetaegeeetet ttgccattcaatccgttggccgtcaaccaatctctgagaaactgcttatcgtaactctcttgcgatttacccacttggtaagtctttt gattccaaaatctagaagaatctggagttaaaacttcatctactagtaccaattcattgttttcgtccagtccaaattcgaatttcgt atcagcaataatgatccccttcaaaagggcgaagttttttgcagcagaatacaactcgaccgccttgacagcgaccttctcac aaatgtetttacetacaateteageagettgtteaatagagatgtttteategtgtteaeeetgtteagetttegttgaaggtgtgaa aatcggagttggaaaggcgtcgctctttgaaggttctcgttttcaaccttgactccatggacagtttttgagttcttgtactctttc catgcacttccagtgatgtaacctctgacaatggcttccaaaggtatcagtctgtgcttttttactatcaaggatcgtccctctaat tgagatttgtatttttetteagacagttttgatggtagtaaagcaaagactteettgteattagaageaaceaaatgattetttatgta gggtgccaaaaaatcaaaccagaaaactgagagctgagtcaaaatctttcccttatcaggaataccgtttgtcataatcacatc gtaageggagataeggteagttgegaegaacageaagttgtteteategaetgeataaatgtetetaaeettteetttggegatt

5

10

15

20

25

aaaggtaggattccgtccagatcagtgttcacaatggacatacttggaaggatacagcaaagtgtgttggaagcgatgacac atggaa aggaa attttc gagtttcct agagtagt at attggggcggtgaa agttcagatgtttaatgcttaatactctt at actcttcc.aaagcgcccaagtgtttctgccaacctgactttttctgaataatgaatcgttcaagtggagtatttaaaccatgattaagttacgt ggagtgggaaataccaagaaaacatcaaactcgaatgattttcccaaacccctaccacaagatattcatcagctgcgagat gtatcaaaaatgaagcetgcatctctcaggcaaatggcattctgacatcctcttgattagaatctagcaagaceggtcttctcgt aagtgcccaacttgaactgaggaacagtcatgtctaaggctacaaactcaatgatgatgatgatgatggtggacggcgctatt cagatectettetgagatgagtttttgttegggeeeaaaaataaetteeeaatetteagttatgteaagegataggttaagaatgg ttgtgttgtaaattattctttgcgataatgattttttcaatattggtattcctcaaagtattgtggtgaatgcctgtcaaattctcggga atatgacttcgaacattttttaaggtattgttttcgaaaatgaactgagtttctacgtactcacctctttggtagccaaaagtttctcc at catca a cata a agatete caa eggete gteet egg tate agg gg et at a act at taca tat gg at egt ttt te at ta acat tg gate get egget ea agatette tata et tatettte at agt gata at gt gacege et te aat aat aat gaat tittat ee aat gg t geaga aat at tetti tatee at agt gacaga aat at tetti tatee at gata et at a te tatee at gata et at te tatee at a te ttgattgaccaggetccgtgacaggtttgactaatagacctgaattactccagtaaaattggttatcgatatgatacaattcagca g caggaa at at ctca at t g at a at at cacgt act at c g act t ca a a g g t cat t g at t a g g t ct at t g at a g g t c at t g at a g g at a g g t c at t g at a g gaagccagctatgtcggctcctataaatggcataccagcaatgttgtttgacagaaccataggaatggaaatctttaagtaatcc cgettateggatggtgaataaategattttattgegtegtaagtagetteatgeactgatagaceatatatgttatggacggatetttecteaatgtaattgtegtgaateaaatettttggagetgtggtetetgggeeategaaaategaaggetegtteatateatteea aatgaataaattagttaaatcagccggcagatccataaaccgttcgaaaaaggacttccaaatcttttggccatatttgcttatg ccct g teact g at the at a tetret that a tengen a large a tengen a grant to the consistency of the consist

ggaatcatatgagcatccatctgagagtccactgtgagaacgtccatctcatcattataattccatctacattgatggtaccctat agaggaaatgggcggtaaaaagggtctaccagtcaaatcggtaaatttgtcaatgatagttggaatatctggccccagggac atgactacatctatgacaccattttcggagatccaatgagtcatcgttttatttttactggtgtcatactttatgtctacccaagtgtc agctg cattg acccaaa agatag at g t g ac g aa gat g aa a acat g aat g g at c g aaccgt ac at t g g t t g g c t g acccgt accept a comparison of the comparisongatgttgtactcaaagacatcaacgttgaaaagcctgtagggttcctttccacctgaagtgtccatcagccttagcgacgtcgc atgttccggtataccgtagacattagtagaacccatgaaagagaaatctagcgcaaccgattcaggccccaaaggcataga gtcatgctttgaatacaagaaattgtccttaaacatgttgaaagttgtttcttctggcagcacgtgtgcgaagttttcctgcttagtt ctatgatgttcaatgttcaggaaattttgctcgtttacaataagtttcagcgcattttgccagtaaactttcaattgaaaaggttcag caaagattictacggatacatcaccgtttcgaagatgaaatgtgtctgcagtggagtttgaaagtgacaaaaatgaagatatttt ttatagtgaacettactgagtgatcctgtaaaaaagagagagagaatgggaactgaacggctatatcatcgccctccaatcttggtatagttttaattatggtagcatgaagcacattetetaaaggategtgtgcaatagaeteggegtecaetttgtaatagcagt aacgcatgcgaaaaagcggtaaagaagaccaattggcatacgagccatttcaaaaggaccatctcgaggtaccgatccga gacggccggctgggccacgtgaattcgactgctattatctctgtgtgtatgtgtgtattgggcaacaagagcttgtgaatctgt ttattatagtgtcagcgatactatacaatctacgatgcccgatgtcggcatacagcacattattagatccaaaatttccttaatttc ctattcacgttatatatattaaccagaatttatccgttgaattgcttaatcgacttcttccacggttggtccgctgtctccgcctggg gcagcaccacctggggcaccgccagctgcgccagctccgccagggaaacctccagggaagccaccaggagctccacc aggagetee accage agetee at agaact tgete att att gggt tage a act tettee atteet tt geet gteet tg tae tegte en the test grant to the test grant to the test grant test grant to the test grant test grant to the test grant test grant test grant to the test grant testtgtggaagcagattgtgactcatcatagatctgatctcat

SEQ ID NO: 24 pGAPZAglsIIHDEL

5

. 10

15

20

25 tegagatggteettttgaaatggetegtatgeeaattggtettetttacegetttttegeatgegtttacegactatetattaaagaa gtgtgegeaatetgggttttgeeatagaaacagggtttatgeagaaatattgeeaaateteateactgetattacaaagtgga egeegagtetattgeacaegateetttagagaatgtgetteatgetaceataattaaaactataceaagattggagggegatga tatageegtteagtteecattetetetettttttacaggateacteagtaaggtteactataaatgagaaagagagaatgeeaa ecaacageageggtttgttgatetetteacaaeggtteaatgagaacetggaagtaegeattegacaagaaattteaagaga

5

10

15

20

25

ttgtcactttcaaactccactgcagacacatttcatcttcgaaacggtgatgtatccgtagaaatctttgctgaaccttttcaattg aaagtttactggcaaaatgcgctgaaacttattgtaaacgagcaaaatttcctgaacattgaacatcatagaactaagcagga aaacttegeacaegtgetgeeagaagaaacaacttteaaeatgtttaaggaeaatttettgtatteaaageatgaetetatgeett tggggcctgaatcggttgcgctagatttctctttcatgggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggttctactaatgtctacggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgctaaggtataccggaacatgcgacgtcgcacggctgatggacacttcaggtggaaaggaaccctacaggcttttcaacgttgatgtctttgagtacaacatcggtaccagccaac agtatgacaccagtaaaaataaaacgatgactcattggatctccgaaaatggtgtcatagatgtagtcatgtccctggggcca gat attece a act at cattgace a atttace gatttgactggt a gaccetttttace gece atttect cattag ggt accate a at gata the cattgace and the cattgace and the cattag gradual content of the cattgace and the cattgace and the cattag gradual cattgace and the cattag gradual cattag gradual cattgace and the cattag gradual cattag gradualacttggagtatacgaacgacaaaaaatattttacttggaagcagcactcetttcccaatccaaaaaggctgttatccaaattaaa gtagcagtcaaggatcacaatggaaatgactatgtaggtcattgctggccaggtaattctatatggattgataccataagcaaa tatggccaaaagatttggaagtcctttttcgaacggtttatggatctgccggctgatttaactaatttattcatttggaatgatatga acgageettegattttegatggeecagagaceacageteeaaaagatttgatteacgacaattacattgaggaaagateegte cataacatatatggtctatcagtgcatgaagctacttacgacgcaataaaatcgatttattcaccatccgataagcgtcctttcct tetaacaagggetttttttgeeggeteteaacgtactgetgecacatggactggtgacaatgtggecaattgggattacttaaag atttccattcctatggttctgtcaaacaacattgctggtatgccatttataggagccgacatagctggctttgctgaggatcctac acctga attgattgca cgttggtacca agcgggcttatggtacccattttttagagca cacgcccatatagacacca agagaaccat gttt cata a at caa gt gt cac t gg at ttccg at a at ga at cca at gttt at t ga a caccet ga at tt gct ga at t gt at cat at the control of the control ofcgataaccaattttactggagtaattcaggtctattagtcaaacctgtcacggagcctggtcaatcagaaacggaaatggttttc ccacccggtatattctatgaattcgcatctttacactcttttataaacaatggtactgatttgatagaaaagaatatttctgcaccat tggataaaattccattatttattgaaggcggtcacattatcactatgaaagataagtatagaagatcttcaatgttaatgaaaaac gatecatatgtaatagttatageeeetgataeegagggaegageegttggagatetttatgttgatgatggagaaaettttgget accaaagaggtgagtacgtagaaactcagttcattttcgaaaacaataccttaaaaaatgttcgaagtcatattcccgagaattt gacaggcattcaccacaatactttgaggaataccaatattgaaaaaatcattatcgcaaagaataatttacaacacaacataac gttgaaagacagtattaaagtcaaaaaaaatggcgaagaaagttcattgccgactagatcgtcatatgagaatgataataaga teaceattettaacetategettgacataactgaagattgggaagttatttttgggeeegaacaaaaacteateteagaagagg

atctgaatagcgccgtcgaccacgacgaactgtgagttttagccttagacatgactgttcctcagttcaagttgggcacttacg agaagaccggtettgetagattetaateaagaggatgteagaatgeeatttgeetgagagatgeaggetteatttttgataetttt ttattigtaacctatatagtataggattttttttgtcatttigtttettetegtaegagettgeteetgateageetatetegeagetgat gaatatettgtggtaggggtttgggaaaateattegagtttgatgtttttettggtattteecacteetetteagagtacagaagatt aagtgagaccttcgtttgtgcggatcccccacacaccatagcttcaaaatgtttctactccttttttactcttccagattttctcgga ctccgcgcatcgccgtaccacttcaaaacacccaagcacagcatactaaattttccctcttttcttcctctagggtgtcgttaatta cccgtactaaaggtttggaaaagaaaaaagagaccgcctcgtttctttttcttcgtcgaaaaaggcaataaaaatttttatcacg tttctttttcttgaaattttttttttttagttttttctctttcagtgacctccattgatatttaagttaataaacggtcttcaatttctcaagtttc aattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaactaaaccatggccaagttgaccagtgccgt aggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtgccggacaa caccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccgg gcaactgcgtgcacttcgtggccgaggagcaggactgacacgtccgacggcgcccacgggtcccaggcctcggagat ccgtcccccttttcctttgtcgatatcatgtaattagttatgtcacgcttacattcacgcctccccccacatccgctctaaccgaa ttaatttgcaagctggagaccaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg cgtttttccataggctccgccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacagga ctataaagataccaggegtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtcc gcetttetecettegggaagegtggegettteteaatgeteaegetgtaggtateteagtteggtgtaggtegttegeteeaage tgggctgtgtgcacgaacccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaag acacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttctt gaagtggtggcetaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaa gagttggtagetettgateeggeaaacaaceacegetggtageggtggttttttgtttgeaageageagattaegegeaga aaaaaaggatctcaagaagatcetttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttg gtcatgcatgagatcagatcttttttgtagaaatgtcttggtgtcctcgtccaatcaggtagccatctctgaaatatctggctccgt tgcaactccgaacgacctgctggcaacgtaaaattctccggggtaaaacttaaatgtggagtaatggaaccagaaacgtctc

10

15

20

SEQ ID NO: 25 pGAPADE1glsIIHDEL

5

10

15

20

25

cgtactcacctctttggtagccaaaagtttctccatcatcaacataaagatctccaacggctcgtccctcggtatcaggggctat tggaattttatccaatggtgcagaaatattettttetatcaaateagtaceattgtttataaaagagtgtaaagatgegaatteatag aatataccgggtgggaaaaccatttccgtttctgattgaccaggctccgtgacaggtttgactaatagacctgaattactccag taaaattggttatcgatatgatacaattcagcaaattcagggtgttcaataaacattggattcattatcggaaatccagtgacact tgatttatgaaacatggtgtataaggtaggtagcaggaaatatctcaattggataatatcacgtactatcgacttcaaaggttcat tgaataagtatggttetettetettggtgtetatatgggegtgtgetetaaaaaaatgggtaecataageeegettggtaecaaegt gcaatcaattcaggtgtaggatcctcagcaaagccagctatgtcggctcctataaatggcataccagcaatgttgtttgacag aaccataggaatggaaatctttaagtaatcccaattggccacattgtcaccagtccatgtggcagcagtacgttgagagccg gcaaaaaaagcccttgttagaaggaaaggacgcttatcggatggtgaataaatcgattttattgcgtcgtaagtagcttcatgc actgatagaccatatatgttatggacggatctttcctcaatgtaattgtcgtgaatcaaatcttttggagctgtggtctctgggcca tegaaaategaaggetegtteatateatteeaaatgaataaattagttaaateageeggeagateeataaacegttegaaaaag gact to caa a tottt t gecat at tt get tat gg tat caat coat a gaat tacct gg coag caat gacct a cat agt cat tt coat a gact to caa a tott to cat a gact to cat a gact taccat agt cat to cat a gact to catactecaagtecaaccaaataaaategtaaggaateatatgagcatecatetgagagtecaetgtgagaacgtecateteate attata attocatcta cattgat gg taccct at agagga a at gg gc gg taaa aa gg gt ctacca gt caa at cg gt aa at tt gt caar at the state of theat gat a gtt ggaat at et ggeece ag ggae at gaet acate tat gae accatt tit eg gag at cea at gag te at eg titt at titt tat at gae accatt tit eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg gag at cea at gag te at eg titt at titt ta at gar accat titt eg titt at titt ta at gar accat titt eg titt at titt ta at gar accat titt eg titt at titt titt at titt titt at gar accat titt eg titt at titt titt at gar accat titt eg titt at titt titt at titt titt at gar accat titt eg titt at titt titt at titt titt at gar accat titt eg titt at titt titt at gar accat titt eg titt at titt titt at gar accat titt eg titt at gar accat titt eg titt at titt titt at gar accat titt eg titt at gar accat titt eg titt at titt titt at gar accat titt eg titt at gar accat titt eg titt at titt titt at gar accat titt eg titt at gar accat tittgaagtgtccatcagccttagcgacgtcgcatgttccggtataccgtagacattagtagaacccatgaaagagaaatctagcgcaaccgattcaggccccaaaggcatagagtcatgctttgaatacaagaaattgtccttaaacatgttgaaagttgtttcttctg

geageaegtgtgegaagtttteetgettagttetatgatgtteaatgtteaggaaattttgetegtttaeaataagttteagegeatt ttgccagtaaactttcaattgaaaaggttcagcaaagatttctacggatacatcaccgtttcgaagatgaaatgtgtctgcagtg actggtcctgttcgcctcctcttgaaatttcttgtcgaatgcgtacttccaggtctcattgaaccgttgtgaagagatcaacaaacctgaacggctatatcatcgccctccaatcttggtatagttttaattatggtagcatgaagcacattctctaaaggatcgtgtgcaa tagacteggegteeactttgtaatageagtgatgagatttggeaatattttetgeataaaccetgtttetatggeaaaacceagat tgegeacaettetttaatagatagteggtaaaegeatgegaaaaageggtaaagaagaecaattggeataegageeatttea aaaggaccatctcgaggtaccgatccgagacggccggctgggccacgtgaattcctcgtttcgaaatagttgttcaattgatt gaaatagggacaaataaattaaatttaaagtctttgggtcaggagaaaccaaaattgggaaaggtgttcgccttttatattcgat tetggtggtttecaataateteatgacatgegteegeeegetattattgecagegaeggeegggacttttecatecetgggetg ctaggtcgggtacacgacetccgttttacccgcaacgtaatgctgggaagagcattgctgcaagggggccgtagaagaag ttactccacatttaagttttaccccggagaattttacgttgccagcaggtcgttcggagttgcaacggagccagatatttcagag atggctacctgattggacgaggacaccaagacatttctacaaaaaagatctgatctcatcgaccggctgcattaatgaatcgg ctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacat gtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccctg acgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttcccct ggaageteectegtgegeteteetgtteegaeeetgeegettaeeggataeetgteegeettteteeettegggaagegtgge gettteteatageteaegetgtaggtateteagtteggtgtaggtegttegeteeaagetgggetgtgtgeaegaaeceeegt teagecegacegetgegeettateeggtaaetategtettgagteeaaceeggtaagacaegaettategeeaetggeagea gccactggtaacaggattagcagagggaggtatgtagggggtgctacagaggtcttgaagtggtggcctaactacggctacactaga agga cag tatt tgg tatct geg ctct get gaag ccag ttacct tcggaaa aa agag tt gg tag ctct tgat ccgg caaa caa accaccget ggt ag eggt ggttttttt gt tt gcaag cag cag at tacgeg cag aa aa aa aa ggat ct caag aa gat cetture ag aa gat comment of the cotgatettttetaeggggtetgaegeteagtggaaegaaaeteaegttaagggattttggteatgagattateaaaaaggatett a teagtg aggeac ctate teageg at etg tet at the gittest ceatagtt geet gaet ecceg tegt gaga ta act acgataegggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataa

10

15

20

a agctag agta agtag ttcgccagt taat agtttgccaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctc cttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgteatgecateegtaagatgettttetgtgactggtgagtacteaaceaagteattetgagaatagtgtatgeggegacegagtt gctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactetcaaggatettaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatettcagcatet atcaacgataaacggaatggttacttgaatgatttcactttatgatcattgtttactaattacctaaataggattttatatggaattgg aagaataagggaaatttcagatgtctgaaaaaggcgaggagggtactaatcattcaagcccatttcttgccagtaattgcttca taagetteaatataettttetttaetettgatageaatttetgeateeatggetaegeeetetttgeeatteaateegttggeegteaa ccaatctctgagaaactgcttatcgtaactctcttgcgatttacccacttggtaagtcttttgattccaaaatctagaagaatctgg agttaaaacttcatctactagtaccaattcattgttttcgtccagtccaaattcgaatttcgtatcagcaataatgatccccttcaaa agggcgaagttttttgcagcagaatacaactcgaccgccttgacagcgaccttctcacaaatgtctttacctacaatctcagca gettgttcaatagagatgttttcatcgtgttcaccctgttcagctttcgttgaaggtgtgaaaatcggagttggaaaggcgtcgct ctettgaaggttetegtttteaacettgaeteeatggaeagtttttgagttettgtaetettteeatgeactteeagtgatgtaacete tgacaatggcttccaaaggtatcagtctgtgcttttttactatcaaggatcgtccctctaattgagatttgtatttttcttcagacagt tttgatggtagtaaagcaaagacttccttgtcattagaagcaaccaaatgattctttatgtagggtgccaaaaaatcaaaccagaaaactgagagctgagtcaaaatctttcccttatcaggaataccgtttgtcataatcacatcgtaagcggagatacggtcagtt gegaegaacageaagttgtteteategaetgeataaatgtetetaacettteetttggegattaaaggtaggatteegteeagat cagtgttcacaatggacatacttggaaggatacagcaaagtgtgttggaagcgatgacacatggaaaggaatttttcgagttt caacetgacttttttctgaataatgaatcgttcaagtggagtatttaaaccatgattaagttacgtgatttggcactggataaggtc gaaaaataccgtattcataaacgattattggtaaaagttacaaaataccactaattacggagaagcttagtaacagttatcatct ettggtegattaaegettaeaattteeattegeeatteaggetgegeaaetgttgggaagggegateggtgeggeetetteg ctattacgccagggcctcgaggcacaaacgaacgtctcacttaatcttctgtactctgaagaggagtgggaaataccaagaa aaacatcaaactcgaatgattttcccaaacccctaccacaagatattcatcagctgcgagataggctgatcaggagcaagct cgtacgagaagaacaaaatgacaaaaaaatcctatactatataggttacaaataaaaaagtatcaaaaatgaagcctgca

10

15

20

tctctcaggcaaatggcattctgacatcctcttgattagaatctagcaagaccggtcttctcgtaagtgcccaacttgaactgag
gaacagtcatgtctaaggctaaaactcacagttcgtcgtggtcgacggcgctattcagatcctcttctgagatgagtttttgttc
gggcccaaaaataacttcccaatcttcagttatgtcaagcgataggttaagaatggtgatcttattatcattctcatatgacgatc
tagtcggcaatgaactttcttcgccattttttttgactttaatactgtctttcaacgttatgttgtgttgtaaattattctttgcgataatg
attttttcaatattggtattcctcaaagtattgtggtgaatgcctgtcaaattctcgggaatatgacttcgaacattttttaaggtattg
ttttcgaaaatgaactgagtttcta

SEQ ID NO: 26

GACGAGATCTTTTTTCAGACCATATGACCGG

10

5

SEQ ID NO: 27

GCGGAATTCTTTTCTCAGTTGATTTGTTTGT

SEQ ID NO: 28

15 GCG GGT CGA CCA CGA CGA ACT GTG AGT TTT AGC CTT AGA CAT GAC

SEQ ID NO: 29

CAG GAG CAAA GCT CGT ACG AG

We claim:

5

20

 A vector capable of expressing an α-1,2-mannosidase or a functional part thereof in a methylotrophic yeast strain, comprising a nucleotide sequence coding for said α-1,2-mannosidase or said functional part.

- 2. The vector of claim 1, wherein said α -1,2-mannosidase is a protein from a fungal species.
- 3. The vector of claim 2, wherein said fungus is *Trichoderma reesei*.
 - 4. The vector of claim 1, wherein said α -1,2-mannosidase is a protein from a mammalian species.
- 15 5. The vector of claim 4, wherein said α -1,2-mannosidase is murine α -1,2-mannosidase IA or IB.
 - 6. The vector of claim 1, wherein said α -1,2-mannosidase or said functional part is tagged with an ER-retention signal.
 - 7. The vector of claim 6, wherein said ER-retention signal comprises peptide HDEL.
- 8. The vector of claim 1, wherein the nucleotide sequence coding for
 25 said α-1,2-mannosidase or said functional part is operably linked to a promoter and a
 3' termination sequence.

9. The vector of claim 8, wherein said promoter is the promoter of a gene selected from the group consisting of AOXI, AOXII, GAP, and FLD.

- 10. A vector selected from the group consisting of pGAPZMFManHDEL, pGAPZMFManMycHDEL, pPICZBMFManMycHDEL, pGAPZmManHDEL, pGAPZmMycManHDEL, pPIC9mMycManHDEL and pGAPZmMycManHDEL.
- 11. A vector capable of expressing a glucosidase II or a functional part10 thereof in a methylotrophic yeast strain, comprising a nucleotide sequence coding for said glucosidase II or said functional part.
 - 12. The vector of claim 11, wherein said glucosidase II is a protein from a fungal species.

15. The vector of claim 12, wherein sai

- 13. The vector of claim 12, wherein said fungus is *Saccharomyces* cerevisiae.
- 14. The vector of claim 11, wherein said glucosidase II is a protein20 from a mammalian species.
 - 15. The vector of claim 11, wherein said glucosidase II or said functional part is tagged with an ER-retention signal.
- 25 16. The vector of claim 15, wherein said ER-retention signal comprises peptide HDEL.

17. The vector of claim 11, wherein the nucleotide sequence coding for said α -1,2-mannosidase or said functional part is operably linked to a promoter and a 3' termination sequence.

- 5 18. The vector of claim 17, wherein said promoter is the promoter of a gene selected from the group consisting of AOXI, AOXII, GAP, and FLD.
- 19. A vector having the designation pGAPZAGLSII, pPICZAGLSII, pAOX2ZAGLSII, pYPTIZAGLSII, pGAPADEglsII, pPICADEglsII,
- pAOX2ADEglsII, pYPTIADEglsII, pGAPZAglsIIHDEL and pGAPADEglsIIHDEL.

- 20. A vector for disrupting the Och1 gene in a methylotrophic yeast strain, comprising a portion of the Och1 gene and a selectable marker gene, wherein said portion of the Och1 gene and said selectable marker gene are linked in such a way to effect the disruption of the genomic Och1 gene in said methylotrophic yeast strain.
 - 21. A vector having the designation pBLURA5'PpOCH1.
- 22. A method of reducing the glycosylation on proteins produced from
 a methylotrophic yeast, comprising transforming said yeast with any one of the vectors of claims 1-21.
 - 23. The method of claim 22, wherein said yeast is *Pichia pastoris*.
- 24. The method of claim 23, wherein said yeast is a *Pichia pastoris* strain selected from GS115 (NRRL Y-15851), GS190 (NRRL Y-18014), PPF1 (NRRL Y-18017), PPY12-OH, yGC4, or derivatives thereof.

25. The method of claim 22, 23 or 24, wherein said yeast has been genetically engineered to expresses a heterologous protein.


- 26. A genetically engineered strain of a methylotrophic yeast, wherein said strain is transformed with at least one of the vectors of claims 1-21.
 - 27. A method of reducing the glycosylation of a heterologous glycoprotein expressed from a methylotrophic yeast, comprising transforming cells of said methylotrophic yeast with at least one of the vectors of claims 1-21, and producing said glycoprotein from the transformed cells.


10

- 28. A method of producing a glycoprotein with reduced glycosylation in a methylotrophic yeast, comprising transforming cells of said methylotrophic yeast with at least one of the vectors of claims 1-21 and with a nucleotide sequence capable of expressing said glycoprotein in said yeast, and producing said glycoprotein from the transformed cells.
 - 29. A glycoprotein produced by the method of claim 27 or 28.
- 30. The glycoprotein of claim 29, wherein said glycoprotein has a reduced immunogenicity as relative to the glycoprotein produced from a wild type strain of said methylotrophic yeast.
- 31. The glycoprotein of claim 29, wherein said glycoprotein is suitable for use in human therapeutics.
 - 32. A kit comprising any of the vectors of claims 1-21.

33. The kit of claim 32, further comprising a methylotrophic yeast strain.

34. A kit comprising the methylotrophic yeast strain of claim 26.









FIGURE 2






FIGURE 4




FIGURE 5

Glucose units




FIGURE 6




FIGURE 7




FIGURE 8

Pichia OCH1 Genomic fragment




FIGURE 9




FIGURE 10





FIGURE 11

Glsll Pichia ex---ssion vector pGAPZ(A)glsll



GlsII Pichia ex ression vector pAOX2Z(A)gls¹¹




FIGURE 13

GlsII Pichia ex ression vector pPICZ(A)glsII





FIGURE 14

GlsII Pichia ex_ ession vector pYPT1Z(A)glsI!



GlsII Pichia expression vector pGAPADE1glsII




FIGURE 16

GlsII Pichia expression vector pAOX2ADE1glsII




FIGURE 17

GlsII Pichia expression vector pPICADE1glsII




FIGURE 18

GlsII Pichia expression vector pYPT1ADE1glsII




FIGURE 19

GlsII Pichia expression vector pGAPZ(A)glsIIHDEL




FIGURE 20

GlsII Pichia expression vector pGAPADE1glsIIHDEL




FIGURE 21

Glucosidase II assay on commercially available alpha-glucosidase




FIGURE 22

Glucosidase II assay on heterologously expressed Pichia protein




FIGURE 23